Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 696 articles:
HTML format



Single Articles


    September 2023
  1. BOSKOVIC P, Wilke N, Man KH, Lichter P, et al
    BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression.
    Neuro Oncol. 2023 Sep 28:noad190. doi: 10.1093.
    PubMed     Abstract available


  2. KRESBACH C, Holst L, Schoof M, Leven T, et al
    Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
    Neuro Oncol. 2023 Sep 28:noad191. doi: 10.1093.
    PubMed     Abstract available


  3. REMES TM, Suo-Palosaari MH, Arikoski PM, Harila M, et al
    Radiotherapy-induced vascular cognitive impairment 20 years after childhood brain tumor.
    Neuro Oncol. 2023 Sep 27:noad186. doi: 10.1093.
    PubMed     Abstract available


  4. SAIJO A, Ogino H, Butowski NA, Tedesco MR, et al
    A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
    Neuro Oncol. 2023 Sep 27:noad185. doi: 10.1093.
    PubMed     Abstract available



  5. Correction to: Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Neuro Oncol. 2023 Sep 26:noad180. doi: 10.1093.
    PubMed    


  6. BIHN JR, Cioffi G, Waite KA, Kruchko C, et al
    Brain Tumors in United States Military Veterans.
    Neuro Oncol. 2023 Sep 22:noad182. doi: 10.1093.
    PubMed     Abstract available


  7. ODDE D
    Glioblastoma Cell Invasion: Go? Grow? Yes.
    Neuro Oncol. 2023 Sep 22:noad178. doi: 10.1093.
    PubMed    


  8. MILDE T, Fangusaro J, Fisher MJ, Hawkins C, et al
    Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
    Neuro Oncol. 2023 Sep 21:noad125. doi: 10.1093.
    PubMed     Abstract available


  9. DESHPANDE K, Martirosian V, Nakamura BN, Das D, et al
    SRRM4-mediated REST to REST4 dysregulation promotes tumor growth and neural adaptation in breast cancer leading to brain metastasis.
    Neuro Oncol. 2023 Sep 16:noad175. doi: 10.1093.
    PubMed     Abstract available


  10. KRAMER C, Kilian M, Chih YC, Kourtesakis A, et al
    NLGN4X TCR transgenic T cells to treat gliomas.
    Neuro Oncol. 2023 Sep 16:noad172. doi: 10.1093.
    PubMed     Abstract available


  11. JOHNSON TS, MacDonald TJ, Pacholczyk R, Aguilera D, et al
    Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial.
    Neuro Oncol. 2023 Sep 16:noad174. doi: 10.1093.
    PubMed     Abstract available


  12. TOBOCHNIK S, Dorotan MKC, Ghosh HS, Lapinskas E, et al
    Glioma genetic profiles associated with electrophysiologic hyperexcitability.
    Neuro Oncol. 2023 Sep 15:noad176. doi: 10.1093.
    PubMed     Abstract available


  13. MISHRA DK, Popovski D, Morris SM, Bondoc A, et al
    Preclinical Pediatric Brain Tumor Models for Immunotherapy: Hurdles and a Way Forward.
    Neuro Oncol. 2023 Sep 15:noad170. doi: 10.1093.
    PubMed     Abstract available



  14. Correction to: HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES.
    Neuro Oncol. 2023 Sep 13:noad168. doi: 10.1093.
    PubMed    


  15. BRUSCHI M, Midjek L, Ajlil Y, Vairy S, et al
    Diffuse Midline Glioma Invasion and Metastasis Rely on Cell-autonomous Signaling.
    Neuro Oncol. 2023 Sep 13:noad161. doi: 10.1093.
    PubMed     Abstract available



  16. Correction to: Mapping pediatric brain tumors to their origins in the developing cerebellum.
    Neuro Oncol. 2023 Sep 12:noad167. doi: 10.1093.
    PubMed    


  17. AVILA EK, Tobochnik S, Inati SK, Koekkoek JAF, et al
    Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.
    Neuro Oncol. 2023 Sep 12:noad154. doi: 10.1093.
    PubMed     Abstract available


  18. SHI DD, Kaelin WG
    The INDIGO Trial: Precision Medicine Finally Comes to Glioma.
    Neuro Oncol. 2023 Sep 12:noad162. doi: 10.1093.
    PubMed    


  19. CAHILL DP, Dunn GP
    Considering the Extent of Resection in Diffuse Glioma.
    Neuro Oncol. 2023 Sep 7:noad165. doi: 10.1093.
    PubMed    


  20. BROWN AL, Sok P, Raghubar KP, Lupo PJ, et al
    Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumors.
    Neuro Oncol. 2023;25:1698-1708.
    PubMed     Abstract available


  21. CHARBONNEAU M, Harper K, Brochu-Gaudreau K, Perreault A, et al
    The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
    Neuro Oncol. 2023;25:1605-1616.
    PubMed     Abstract available


  22. KARSCHNIA P, Dietrich J, Bruno F, Dono A, et al
    Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance') - a report of the RANO resect group.
    Neuro Oncol. 2023 Sep 4:noad160. doi: 10.1093.
    PubMed     Abstract available


    August 2023
  23. HONG B, Yang E, Su D, Ju J, et al
    EPIC-1042 as a potent PTRF/Cavin1-Caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for Glioblastoma.
    Neuro Oncol. 2023 Aug 31:noad159. doi: 10.1093.
    PubMed     Abstract available


  24. PINSON H, Silversmit G, Vanhauwaert D, Vanschoenbeek K, et al
    Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era.
    Neuro Oncol. 2023 Aug 31:noad158. doi: 10.1093.
    PubMed     Abstract available


  25. MALGULWAR PB, Danussi C, Dharmaiah S, Johnson W, et al
    Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
    Neuro Oncol. 2023 Aug 25:noad155. doi: 10.1093.
    PubMed     Abstract available


  26. GU D, You H, Gao J, You Y, et al
    Reply to "Targeting cholesterol homeostasis through inhibiting: An Achilles' heel for glioblastoma?".
    Neuro Oncol. 2023 Aug 25:noad146. doi: 10.1093.
    PubMed    


  27. SUN Y, Mu G, Xue Z, Wang S, et al
    Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles' heel for glioblastoma.
    Neuro Oncol. 2023 Aug 25:noad145. doi: 10.1093.
    PubMed    


  28. HUANG W, Li J, Zhu H, Qin X, et al
    A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.
    Neuro Oncol. 2023 Aug 24:noad153. doi: 10.1093.
    PubMed     Abstract available


  29. KAN P, Srinivasan VM, Gumin J, Garcia R, et al
    Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics.
    Neuro Oncol. 2023 Aug 21:noad152. doi: 10.1093.
    PubMed     Abstract available


  30. PATEL KS, Yao J, Cho NS, Sanvito F, et al
    pH-Weighted Amine Chemical Exchange Saturation Transfer Echo Planar Imaging (CEST-EPI) Visualizes Infiltrating Glioblastoma Cells.
    Neuro Oncol. 2023 Aug 18:noad150. doi: 10.1093.
    PubMed     Abstract available


  31. FRANCIS SS, Guerra G, Hansen HM, Wendt G, et al
    Inherited polymorphisms in the Human Leukocyte Antigen Region modify the association between varicella-zoster virus antibody reactivity and glioma prognosis.
    Neuro Oncol. 2023 Aug 18:noad122. doi: 10.1093.
    PubMed    


  32. GALLO M
    Prognostic value of integrative genomic approaches for IDH-mutant gliomas.
    Neuro Oncol. 2023 Aug 17:noad151. doi: 10.1093.
    PubMed    


  33. JACKSON ER, Persson ML, Fish CJ, Findlay IJ, et al
    A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma.
    Neuro Oncol. 2023 Aug 17:noad144. doi: 10.1093.
    PubMed     Abstract available


  34. SHENOY G, Connor JR
    A Closer Look at the Role of Iron in Glioblastoma.
    Neuro Oncol. 2023 Aug 4:noad136. doi: 10.1093.
    PubMed     Abstract available


  35. OKONECHNIKOV K, Joshi P, Sepp M, Leiss K, et al
    Mapping pediatric brain tumors to their origins in the developing cerebellum.
    Neuro Oncol. 2023 Aug 3:noad124. doi: 10.1093.
    PubMed     Abstract available


  36. ROBERTS KF, Dahiya SM
    Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
    Neuro Oncol. 2023;25:1450-1451.
    PubMed    


  37. FENG J, Duan Z, Yao K, Gui Q, et al
    Primary papillary epithelial tumor of the sella and posterior pituitary tumor show similar (epi)genetic features and constitute a single neuro-oncological entity.
    Neuro Oncol. 2023;25:1487-1497.
    PubMed     Abstract available


  38. KOJIC M, Maybury MK, Waddell N, Koufariotis LT, et al
    Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening.
    Neuro Oncol. 2023;25:1507-1517.
    PubMed     Abstract available


  39. KROS JM, Rushing E, Uwimana AL, Hernandez-Lain A, et al
    Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
    Neuro Oncol. 2023;25:1443-1449.
    PubMed     Abstract available


  40. ZUCCATO JA, Patil V, Mansouri S, Voisin M, et al
    Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification.
    Neuro Oncol. 2023;25:1452-1460.
    PubMed     Abstract available


  41. PARAQINDES H, Mourksi NE, Ballesta S, Hedjam J, et al
    IDHwt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
    Neuro Oncol. 2023 Aug 2:noad140. doi: 10.1093.
    PubMed     Abstract available


  42. APFELBAUM A, Bandopadhayay P
    The 'LOGGIC' of RNA-sequencing in enhancing diagnoses of pediatric low-grade gliomas.
    Neuro Oncol. 2023 Aug 2:noad142. doi: 10.1093.
    PubMed    



  43. Corrigendum to: USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
    Neuro Oncol. 2023 Aug 1:noad135. doi: 10.1093.
    PubMed    


  44. MONJE M, Cooney T, Glod J, Huang J, et al
    A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC-047).
    Neuro Oncol. 2023 Aug 1:noad141. doi: 10.1093.
    PubMed     Abstract available


    July 2023
  45. ROTH P
    CARs in the brain: can we tackle glioblastoma with engineered NK cells?
    Neuro Oncol. 2023 Jul 31:noad131. doi: 10.1093.
    PubMed    


  46. CHIANG J, Bagchi A, Li X, Dhanda SK, et al
    High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse-Results from the SJYC07 trial and institutional experience.
    Neuro Oncol. 2023 Jul 28:noad130. doi: 10.1093.
    PubMed     Abstract available


  47. YOUNG JS, Morshed RA, Hervey-Jumper SL, Berger MS, et al
    The Surgical Management of Diffuse Gliomas: Current State of Neurosurgical Management and Future Directions.
    Neuro Oncol. 2023 Jul 27:noad133. doi: 10.1093.
    PubMed     Abstract available


  48. LIU RZ, Choi WS, Jain S, Xu X, et al
    Stationary-to-migratory transition in glioblastoma stem-like cells driven by a FABP7-RXRalpha neurogenic pathway.
    Neuro Oncol. 2023 Jul 27:noad134. doi: 10.1093.
    PubMed     Abstract available


  49. WOLIN AR, Vincent MY, Hotz T, Purdy SC, et al
    EYA2 Tyrosine Phosphatase Inhibition Reduces MYC and Prevents Medulloblastoma Progression.
    Neuro Oncol. 2023 Jul 24:noad128. doi: 10.1093.
    PubMed     Abstract available


  50. HALL MD, Kotecha R
    Social Determinants of Health: A Forgotten Risk Factor for Neurocognition in Pediatric Brain Tumor Survivors.
    Neuro Oncol. 2023 Jul 24:noad127. doi: 10.1093.
    PubMed    


  51. PREUSSER M, Geurts M, Hainfellner JA, van den Bent MJ, et al
    What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?
    Neuro Oncol. 2023 Jul 21:noad113. doi: 10.1093.
    PubMed    


  52. MAMATJAN Y, Voisin M, Nassiri F, Moraes FY, et al
    Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in IDH mutant glioma.
    Neuro Oncol. 2023 Jul 20:noad126. doi: 10.1093.
    PubMed     Abstract available


  53. HOU J, Huang P, Xu M, Wang H, et al
    NCAPG promotes the progression of glioblastoma by facilitating PARP1-mediated E2F1 transactivation.
    Neuro Oncol. 2023 Jul 9:noad111. doi: 10.1093.
    PubMed     Abstract available


  54. LAPRIE A, Noel G, Chaltiel L, Truc G, et al
    Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).
    Neuro Oncol. 2023 Jul 7:noad119. doi: 10.1093.
    PubMed     Abstract available


  55. CHANG SM
    Increasing growth and impact of Neuro-Oncology.
    Neuro Oncol. 2023;25:1199.
    PubMed    



  56. Erratum to: METB-13. A SINGLE-CELL GENETIC IN VIVO LINEAGE-TRACING PLATFORM FOR MEDULLOBLASTOMA.
    Neuro Oncol. 2023 Jul 6:noad116. doi: 10.1093.
    PubMed    


  57. POON MTC, Piper RJ, Thango N, Fountain DM, et al
    Variation in postoperative outcomes of patients with intracranial tumors: insights from a prospective international cohort study during the COVID-19 pandemic.
    Neuro Oncol. 2023;25:1299-1309.
    PubMed     Abstract available


  58. WELLER M, Le Rhun E, Van den Bent M, Chang SM, et al
    Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.
    Neuro Oncol. 2023;25:1200-1224.
    PubMed     Abstract available


  59. TRAGER M, Schweizer L, Perez E, Schmid S, et al
    Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
    Neuro Oncol. 2023;25:1286-1298.
    PubMed     Abstract available


  60. RAMMOHAN N, Ho A, Besson P, Kruser TJ, et al
    Whole-brain radiotherapy associated with structural changes resembling aging as determined by anatomic surface-based deep learning.
    Neuro Oncol. 2023;25:1323-1330.
    PubMed     Abstract available


  61. SMOLL NR, Brady Z, Scurrah KJ, Lee C, et al
    Computed tomography scan radiation and brain cancer incidence.
    Neuro Oncol. 2023;25:1368-1376.
    PubMed     Abstract available


  62. NOCH EK, Palma LN, Yim I, Bullen N, et al
    Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.
    Neuro Oncol. 2023 Jul 3:noad117. doi: 10.1093.
    PubMed     Abstract available


    June 2023
  63. VAN SCHAIK J, Schouten-van Meeteren AYN, Vos-Kerkhof E, Janssens GO, et al
    Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study; first results after centralization of care.
    Neuro Oncol. 2023 Jun 29:noad112. doi: 10.1093.
    PubMed     Abstract available


  64. ZHAO Y, Gu S, Li L, Zhao R, et al
    A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma.
    Neuro Oncol. 2023 Jun 28:noad115. doi: 10.1093.
    PubMed     Abstract available


  65. KOLODZIEJCZAK AS, Guerrini-Rousseau L, Planchon JM, Ecker J, et al
    Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
    Neuro Oncol. 2023 Jun 28:noad114. doi: 10.1093.
    PubMed     Abstract available


  66. HANSCH L, Peipp M, Mastall M, Villars D, et al
    Chimeric antigen receptor (CAR) T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
    Neuro Oncol. 2023 Jun 19:noad108. doi: 10.1093.
    PubMed     Abstract available


  67. RATLIFF M, Karimian-Jazi K, Hoffmann DC, Rauschenbach L, et al
    Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.
    Neuro Oncol. 2023 Jun 19:noad109. doi: 10.1093.
    PubMed     Abstract available


  68. KOCAKAVUK E, Johnson KC, Sabedot TS, Reinhardt HC, et al
    Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.
    Neuro Oncol. 2023 Jun 17:noad095. doi: 10.1093.
    PubMed    


  69. CHAN P, Rich JN, Kay SA
    Watching the Clock in Glioblastoma.
    Neuro Oncol. 2023 Jun 16:noad107. doi: 10.1093.
    PubMed     Abstract available


  70. MUELLER S, Kline C, Stoller S, Lundy S, et al
    PNOC015: Repeated convection enhanced delivery (CED) of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    Neuro Oncol. 2023 Jun 15:noad105. doi: 10.1093.
    PubMed     Abstract available


  71. HOTCHKISS KM, Batich KA, Mohan A, Rahman R, et al
    Dendritic cell vaccine trials in gliomas: Untangling the lines.
    Neuro Oncol. 2023 Jun 8:noad088. doi: 10.1093.
    PubMed     Abstract available


  72. KULIESIUTE U, Joseph K, Straehle J, Ravi VM, et al
    Sialic acid metabolism orchestrates transcellular connectivity and signalling in glioblastoma.
    Neuro Oncol. 2023 Jun 8:noad101. doi: 10.1093.
    PubMed     Abstract available


  73. HUANG N, Chen Z, Yang X, Gao Y, et al
    Upstream Open Reading Frame-encoded MP31 Disrupts the Mitochondrial Quality Control Process and Inhibits Tumorigenesis in Glioblastoma.
    Neuro Oncol. 2023 Jun 6:noad099. doi: 10.1093.
    PubMed     Abstract available


  74. XIN L, Tan Y, Zhu Y, Cui X, et al
    EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
    Neuro Oncol. 2023 Jun 5:noad102. doi: 10.1093.
    PubMed     Abstract available


  75. BAILLEUL J, Ruan Y, Abdulrahman L, Scott AJ, et al
    PKM2 rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance.
    Neuro Oncol. 2023 Jun 5:noad103. doi: 10.1093.
    PubMed     Abstract available


  76. SAHM F, Brandner S, Bertero L, Capper D, et al
    Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.
    Neuro Oncol. 2023 Jun 2:noad100. doi: 10.1093.
    PubMed     Abstract available


  77. ALI UM, Withrow DR, Judge AD, Plaha P, et al
    Temporal trends in the incidence of malignant and nonmalignant primary brain and central nervous system tumors by the method of diagnosis in England, 1993-2017.
    Neuro Oncol. 2023;25:1177-1192.
    PubMed     Abstract available


  78. SUN T, Wang Y, Liu X, Li Z, et al
    Deep learning based on preoperative magnetic resonance (MR) images improves the predictive power of survival models in primary spinal cord astrocytomas.
    Neuro Oncol. 2023;25:1157-1165.
    PubMed     Abstract available


  79. ZAYTSEVA M, Valiakhmetova A, Yasko L, Samarin A, et al
    Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis.
    Neuro Oncol. 2023;25:1132-1145.
    PubMed     Abstract available


  80. DEMIRDIZEN E, Al-Ali R, Narayanan A, Sun X, et al
    TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing.
    Neuro Oncol. 2023;25:1031-1043.
    PubMed     Abstract available


  81. LAMBA N, Cagney DN, Catalano PJ, Kim D, et al
    A Genomic Score to Predict Local Control among Patients with Brain Metastases Managed with Radiation.
    Neuro Oncol. 2023 Jun 1:noad098. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  82. KARSCHNIA P, Dono A, Young JS, Juenger ST, et al
    Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
    Neuro Oncol. 2023 May 30:noad074. doi: 10.1093.
    PubMed     Abstract available



  83. Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Neuro Oncol. 2023 May 29:noad091. doi: 10.1093.
    PubMed    



  84. Corrigendum to: Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
    Neuro Oncol. 2023 May 25:noad093. doi: 10.1093.
    PubMed    



  85. Correction to: Progress for patients with melanoma brain metastases.
    Neuro Oncol. 2023 May 19:noad089. doi: 10.1093.
    PubMed    



  86. Corrigendum to: Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
    Neuro Oncol. 2023 May 19:noad094. doi: 10.1093.
    PubMed    


  87. NEHAMA D, Woodell AS, Maingi SM, Hingtgen SD, et al
    Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity.
    Neuro Oncol. 2023 May 14:noad092. doi: 10.1093.
    PubMed     Abstract available



  88. Retraction of: PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
    Neuro Oncol. 2023 May 13:noad081. doi: 10.1093.
    PubMed    


  89. HAASE S, Lowenstein PR, Castro MG
    "Sabotaging the Protein Factory to Overcome Glioma Stem Cell Resistance".
    Neuro Oncol. 2023 May 13:noad090. doi: 10.1093.
    PubMed    


  90. DI NUNNO V, Gatto L, Tosoni A, Bartolini S, et al
    Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent gliobla
    Neuro Oncol. 2023 May 12:noad071. doi: 10.1093.
    PubMed    


  91. ELLINGSON BM, Wen PY, Cloughesy TF
    Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
    Neuro Oncol. 2023 May 11:noad085. doi: 10.1093.
    PubMed    


  92. BURGER MC, Forster MT, Romanski A, Strassheimer F, et al
    Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
    Neuro Oncol. 2023 May 6:noad087. doi: 10.1093.
    PubMed     Abstract available


  93. LAMBA N, Cagney DN, Catalano PJ, Elhalawani H, et al
    Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
    Neuro Oncol. 2023;25:973-983.
    PubMed     Abstract available


  94. ALLEN BD, Alaghband Y, Kramar EA, Ru N, et al
    Elucidating the neurological mechanism of the FLASH effect in juvenile mice exposed to hypofractionated radiotherapy.
    Neuro Oncol. 2023;25:927-939.
    PubMed     Abstract available


  95. HUANG J, Chan SC, Lok V, Zhang L, et al
    Disease burden, risk factors, and trends of primary central nervous system (CNS) cancer: A global study of registries data.
    Neuro Oncol. 2023;25:995-1005.
    PubMed     Abstract available


    April 2023
  96. JO J, Diaz M, Horbinski C, Mackman N, et al
    Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.
    Neuro Oncol. 2023 Apr 26:noad059. doi: 10.1093.
    PubMed     Abstract available


  97. MULE' TN, Hodges J, Wu S, Li Y, et al
    Social Determinants of Cognitive Outcomes in Survivors of Pediatric Brain Tumors Treated with Conformal Radiation Therapy.
    Neuro Oncol. 2023 Apr 26:noad080. doi: 10.1093.
    PubMed     Abstract available


  98. KOEKKOEK JAF, van der Meer PB, Walbert T
    Reply to the letter regarding "Palliative care and end-of-life care in adults with malignant brain tumors".
    Neuro Oncol. 2023 Apr 25:noad069. doi: 10.1093.
    PubMed    


  99. LIU G, Zhang P, Chen S, Chen Z, et al
    FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells.
    Neuro Oncol. 2023 Apr 21:noad079. doi: 10.1093.
    PubMed     Abstract available


  100. MILLER AM, Karajannis MA
    Cerebrospinal fluid: the new frontier for methylome-based diagnostic classification of brain tumors.
    Neuro Oncol. 2023 Apr 20:noad075. doi: 10.1093.
    PubMed    


  101. HARDIN EC, Schmid S, Sommerkamp A, Bodden C, et al
    LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
    Neuro Oncol. 2023 Apr 19:noad078. doi: 10.1093.
    PubMed     Abstract available


  102. BARBIERI F, Bajetto A, Dellacasagrande I, Solari A, et al
    Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.
    Neuro Oncol. 2023 Apr 19:noad076. doi: 10.1093.
    PubMed     Abstract available


  103. CONTRERAS-ZARATE MJ, Alvarez-Eraso KLF, Jaramillo-Gomez JA, Littrell Z, et al
    Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis.
    Neuro Oncol. 2023 Apr 13:noad070. doi: 10.1093.
    PubMed     Abstract available


  104. MISHIMA K, Nishikawa R, Narita Y, Mizusawa J, et al
    Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
    Neuro Oncol. 2023;25:687-698.
    PubMed     Abstract available


  105. LI X, Moreira DC, Bag AK, Qaddoumi I, et al
    The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
    Neuro Oncol. 2023;25:750-760.
    PubMed     Abstract available


  106. FU R, Norris GA, Willard N, Griesinger AM, et al
    Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma.
    Neuro Oncol. 2023;25:786-798.
    PubMed     Abstract available


  107. SELT F, Sigaud R, Valinciute G, Sievers P, et al
    BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma.
    Neuro Oncol. 2023;25:735-747.
    PubMed     Abstract available


  108. STOLTZE UK, Foss-Skiftesvik J, van Overeem Hansen T, Byrjalsen A, et al
    Genetic predisposition and evolutionary traces of pediatric cancer risk: a prospective 5-year population-based genome sequencing study of children with CNS tumors.
    Neuro Oncol. 2023;25:761-773.
    PubMed     Abstract available



  109. Corrigendum to: NCOG-45. DIFFERENTIAL AND DOSE-DEPENDENT EFFECTS OF CRANIAL IRRADIATION ON BRAIN STRUCTURES AND NEUROPSYCHOLOGICAL OUTCOMES IN CHILDREN WITH POSTERIOR FOSSA BRAIN TUMORS TREATED WITH DIFFERENT MODALITIES.
    Neuro Oncol. 2023 Apr 1:noad058. doi: 10.1093.
    PubMed    


    March 2023

  110. Corrigendum to: Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
    Neuro Oncol. 2023 Mar 29:noad062. doi: 10.1093.
    PubMed    


  111. GOENKA A, Song X, Tiek D, Iglesia RP, et al
    Oncogenic Long Non-coding RNA LINC02283 Enhances PDGF Receptor A mediated Signaling and Drives Glioblastoma Tumorigenesis.
    Neuro Oncol. 2023 Mar 29:noad065. doi: 10.1093.
    PubMed     Abstract available


  112. XIE J, Kuriakose T, Bianski B, Twarog N, et al
    ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
    Neuro Oncol. 2023 Mar 27:noad064. doi: 10.1093.
    PubMed     Abstract available


  113. WERNER JM, Wollring MM, Tscherpel C, Rosen EK, et al
    Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib.
    Neuro Oncol. 2023 Mar 24:noad051. doi: 10.1093.
    PubMed    



  114. Corrigendum to: IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Neuro Oncol. 2023 Mar 21:noad048. doi: 10.1093.
    PubMed    


  115. GU D, Zhou F, You H, Gao J, et al
    SREBP2 maintains glioblastoma stem cells through keeping the balance between cholesterol biosynthesis and uptake.
    Neuro Oncol. 2023 Mar 19:noad060. doi: 10.1093.
    PubMed     Abstract available


  116. BAUCHET L, Sanson M
    Deciphering gliomagenesis from GWAS.
    Neuro Oncol. 2023 Mar 14:noad057. doi: 10.1093.
    PubMed    


  117. KUMTHEKAR PU, Avram MJ, Lassman AB, Lin NU, et al
    A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
    Neuro Oncol. 2023;25:557-565.
    PubMed     Abstract available


  118. VOLLMUTH P, Foltyn M, Huang RY, Galldiks N, et al
    Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
    Neuro Oncol. 2023;25:533-543.
    PubMed     Abstract available


  119. SPERDUTO PW, Salama AKS, Anders C
    Progress for Patients with Melanoma Brain Metastases.
    Neuro Oncol. 2023 Mar 8:noad050. doi: 10.1093.
    PubMed    


  120. GROSSMAN SA
    Using Historical Objective Response Rates to Design Single Arm Phase II Trials in Patients with Recurrent Glioblastoma.
    Neuro Oncol. 2023 Mar 7:noad046. doi: 10.1093.
    PubMed    


  121. YANG Y, Brown MC, Zhang G, Stevenson K, et al
    Polio Virotherapy Targets the Malignant Glioma Myeloid Infiltrate with Diffuse Microglia Activation Engulfing the CNS.
    Neuro Oncol. 2023 Mar 2:noad052. doi: 10.1093.
    PubMed     Abstract available


  122. DREXLER R, Gottsche J, Sauvigny T, Schuller U, et al
    Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
    Neuro Oncol. 2023 Mar 1:noad014. doi: 10.1093.
    PubMed    


    February 2023
  123. ROMO CG, Piotrowski AF, Campian JL, Diarte J, et al
    Clinical, Histological and Molecular Features of Gliomas in Adults with Neurofibromatosis Type 1.
    Neuro Oncol. 2023 Feb 25:noad033. doi: 10.1093.
    PubMed     Abstract available


  124. FOSS-SKIFTESVIK J, Li S, Rosenbaum A, Hagen CM, et al
    Multi-ancestry genome-wide association study of 4,069 children with glioma identifies 9p21.3 risk locus.
    Neuro Oncol. 2023 Feb 22:noad042. doi: 10.1093.
    PubMed     Abstract available


  125. MULKEARNS-HUBERT EE, Lathia JD
    DUB-ling down on the epigenetic regulation of cancer stem cells in glioblastoma.
    Neuro Oncol. 2023 Feb 22:noad040. doi: 10.1093.
    PubMed    


  126. DE ROECK L, Gillebert RC, van Aert RCM, Vanmeenen A, et al
    Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis.
    Neuro Oncol. 2023 Feb 21:noad045. doi: 10.1093.
    PubMed     Abstract available



  127. Corrigendum to: Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
    Neuro Oncol. 2023 Feb 21:noac267. doi: 10.1093.
    PubMed    


  128. BHATTACHARYYA S, Oblinger JL, Beauchamp RL, Yin Z, et al
    Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
    Neuro Oncol. 2023 Feb 20:noad037. doi: 10.1093.
    PubMed     Abstract available


  129. ROTTGERING JG, Klein M, Douw L
    Letter regarding "Palliative care and end-of-life care in adults with malignant brain tumors".
    Neuro Oncol. 2023 Feb 18:noad006. doi: 10.1093.
    PubMed    


  130. LASSMAN AB, van den Bent MJ
    What is a glioblastoma?
    Neuro Oncol. 2023 Feb 15:noad044. doi: 10.1093.
    PubMed    


  131. BAGLEY SJ
    Phase 2 trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment.
    Neuro Oncol. 2023 Feb 15:noad043. doi: 10.1093.
    PubMed    


  132. CHANG SM
    Launch of an Editorial Scholars Program for Neuro-Oncology.
    Neuro Oncol. 2023;25:219-220.
    PubMed    


  133. GAO T, Zhang S, Li M
    Intrathecal trastuzumab: What else do we need to consider?
    Neuro Oncol. 2023;25:418-419.
    PubMed    


  134. OBERKAMPF F, Gutierrez M, Trabelsi Grati O, Rhun EL, et al
    Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
    Neuro Oncol. 2023;25:365-374.
    PubMed     Abstract available


  135. MCAFEE SS, Zhang S, Zou P, Conklin HM, et al
    Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome.
    Neuro Oncol. 2023;25:375-385.
    PubMed     Abstract available


  136. UPADHYAYA SA, Campagne O, Billups CA, Orr BA, et al
    Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
    Neuro Oncol. 2023;25:386-397.
    PubMed     Abstract available


  137. LIM YC, Jensen KE, Aguilar-Morante D, Vardouli L, et al
    Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy.
    Neuro Oncol. 2023;25:248-260.
    PubMed     Abstract available


  138. GREGORY TA, Williford GL, Maronge JM, Alfaro K, et al
    An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas.
    Neuro Oncol. 2023 Feb 1:noad007. doi: 10.1093.
    PubMed    


  139. PATEL RV, Yao S, Huang RY, Bi WL, et al
    Application of radiomics to meningiomas: a systematic review.
    Neuro Oncol. 2023 Feb 1:noad028. doi: 10.1093.
    PubMed     Abstract available


    January 2023
  140. ALEMANY M, Todeschini FA, Vidal N, Pons A, et al
    The impact of health system crises on glioblastoma management and outcomes.
    Neuro Oncol. 2023 Jan 30:noac266. doi: 10.1093.
    PubMed    


  141. TONN S, Korshunov A, Obrecht D, Sill M, et al
    Risk prediction in early childhood SHH medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than two subgroups.
    Neuro Oncol. 2023 Jan 30:noad027. doi: 10.1093.
    PubMed     Abstract available


  142. CHEN CH, Chin RL, Hartley GP, Lea ST, et al
    Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease.
    Neuro Oncol. 2023 Jan 27:noad025. doi: 10.1093.
    PubMed     Abstract available


  143. AQUILANTI E, Kageler L, Watson J, Baird DM, et al
    Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume.
    Neuro Oncol. 2023 Jan 24:noad024. doi: 10.1093.
    PubMed     Abstract available


  144. LIU H, Xu C, Diplas BH, Brown A, et al
    Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Neuro Oncol. 2023 Jan 23:noad022. doi: 10.1093.
    PubMed     Abstract available


  145. AJAIB S, Lodha D, Pollock S, Hemmings G, et al
    GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data.
    Neuro Oncol. 2023 Jan 23:noad021. doi: 10.1093.
    PubMed     Abstract available


  146. WANG Z, Wang Y, Chang M, Wang Y, et al
    Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma.
    Neuro Oncol. 2023 Jan 19:noad017. doi: 10.1093.
    PubMed     Abstract available


  147. ALEJO S, Palacios BE, Venkata PP, He Y, et al
    Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double strand break repair and augments efficacy of temozolomide in glioblastoma.
    Neuro Oncol. 2023 Jan 18:noad018. doi: 10.1093.
    PubMed     Abstract available


  148. KOTECHA R, Mehta MP
    Rethinking Classification and Categorization of Resection Extent and its Impact on Patient Survival in Glioblastoma: Was Walter Dandy Ahead of His Time?
    Neuro Oncol. 2023 Jan 16:noad013. doi: 10.1093.
    PubMed    


  149. SAMPSON JH, Singh Achrol A, Aghi MK, Bankiewiecz K, et al
    Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial.
    Neuro Oncol. 2023 Jan 14:noac285. doi: 10.1093.
    PubMed     Abstract available


  150. STERN E, Ben-Ami M, Gruber N, Toren A, et al
    Hypothalamic-Pituitary-Gonadal Function, Pubertal Development and Fertility Outcomes in Male and Female Medulloblastoma Survivors: A Single Centre Experience.
    Neuro Oncol. 2023 Jan 12:noad009. doi: 10.1093.
    PubMed     Abstract available


  151. CAPPER D, Reifenberger G, French PJ, Schweizer L, et al
    EANO guideline on rational molecular testing of gliomas, glioneuronal and neuronal tumors in adults for targeted therapy selection.
    Neuro Oncol. 2023 Jan 12:noad008. doi: 10.1093.
    PubMed     Abstract available


  152. LIGON JA, Sayour EJ
    Spotlighting cellular therapies to advance the treatment of medulloblastoma.
    Neuro Oncol. 2023 Jan 11:noad005. doi: 10.1093.
    PubMed    


  153. LIU X, Kang C
    Bridging deep sequencing to precision oncology in meningiomas.
    Neuro Oncol. 2023 Jan 10:noad004. doi: 10.1093.
    PubMed    



  154. Retraction of: A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
    Neuro Oncol. 2023 Jan 10:noac260. doi: 10.1093.
    PubMed    


  155. ZHANG H, Liu K, Ba R, Zhang Z, et al
    Histological and Molecular Classifications of Pediatric Glioma with Time-dependent Diffusion MRI based Microstructural Mapping.
    Neuro Oncol. 2023 Jan 7:noad003. doi: 10.1093.
    PubMed     Abstract available


  156. ELLINGSON BM, Wen PY, Chang SM, van den Bent M, et al
    Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival.
    Neuro Oncol. 2023 Jan 7:noad002. doi: 10.1093.
    PubMed     Abstract available


  157. KOEKKOEK JAF, van der Meer PB, Pace A, Hertler C, et al
    Corrigendum to: Palliative care and end-of-life care in adults with malignant brain tumors.
    Neuro Oncol. 2023;25:212.
    PubMed    


  158. FORTIN ENSIGN SP, Jenkins RB, Giannini C, Sarkaria JN, et al
    Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
    Neuro Oncol. 2023;25:28-36.
    PubMed     Abstract available


  159. HOANG-XUAN K, Deckert M, Ferreri AJM, Furtner J, et al
    European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
    Neuro Oncol. 2023;25:37-53.
    PubMed     Abstract available


  160. DE RUITER MB, Groot PFC, Deprez S, Pullens P, et al
    Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI.
    Neuro Oncol. 2023;25:167-176.
    PubMed     Abstract available


  161. DE ALMEIDA MAGALHAES T, Alencastro Veiga Cruzeiro G, Ribeiro de Sousa G, Englinger B, et al
    Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.
    Neuro Oncol. 2023;25:185-198.
    PubMed     Abstract available


  162. GUERRA G, McCoy L, Hansen HM, Rice T, et al
    Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma.
    Neuro Oncol. 2023 Jan 4:noac283. doi: 10.1093.
    PubMed     Abstract available


  163. XIE Y, He L, Zhang Y, Huang H, et al
    Wnt Signaling Regulates MFSD2A-dependent Drug Delivery through Endothelial Transcytosis in Glioma.
    Neuro Oncol. 2023 Jan 2:noac288. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  164. ZISI A, Kanellis DC, Moussaud S, Karlsson I, et al
    Small Molecule-mediated Disruption of Ribosome Biogenesis Synergizes With FGFR Inhibitors to Suppress Glioma Cell Growth.
    Neuro Oncol. 2022 Dec 30:noac286. doi: 10.1093.
    PubMed     Abstract available


  165. APPS JR, Martinez-Barbera JP
    A promising future for hypothalamic dysfunction in craniopharyngioma.
    Neuro Oncol. 2022 Dec 27:noac284. doi: 10.1093.
    PubMed    


  166. PREUSSER M, van den Bent MJ
    Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
    Neuro Oncol. 2022 Dec 23:noac281. doi: 10.1093.
    PubMed    


  167. ALPEN K, Vajdic CM, MacInnis RJ, Milne RL, et al
    Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26.
    Neuro Oncol. 2022 Dec 20:noac279. doi: 10.1093.
    PubMed     Abstract available


  168. STUNDON JL, Ijaz H, Gaonkar KS, Kaufman RS, et al
    ALT in Pediatric High-Grade Gliomas Can Occur without ATRX Mutation and is Enriched in Patients with Pathogenic Germline MMR Variants.
    Neuro Oncol. 2022 Dec 20:noac278. doi: 10.1093.
    PubMed     Abstract available


  169. IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
    Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
    Neuro Oncol. 2022 Dec 19:noac270. doi: 10.1093.
    PubMed    



  170. Corrigendum to: Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-beta signaling in recurrent tumors.
    Neuro Oncol. 2022 Dec 16:noac265. doi: 10.1093.
    PubMed    


  171. MILLER JJ, Arrillaga-Romany I
    IDH-mutant glioma: A new IDH1 inhibitor moves forward.
    Neuro Oncol. 2022 Dec 16:noac275. doi: 10.1093.
    PubMed    


  172. TAO W, Lei H, Luo W, Huang Z, et al
    NIR Drives Glioblastoma Growth by Promoting Ribosomal DNA Transcription in Glioma Stem Cells.
    Neuro Oncol. 2022 Dec 15:noac272. doi: 10.1093.
    PubMed     Abstract available


  173. HAO X, Bahia R, Cseh O, Bozek D, et al
    BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
    Neuro Oncol. 2022 Dec 15:noac271. doi: 10.1093.
    PubMed     Abstract available


  174. BARNHOLTZ-SLOAN JS
    Expanding our knowledge of brain tumor overall survival trends at a global scale.
    Neuro Oncol. 2022 Dec 14:noac268. doi: 10.1093.
    PubMed    


  175. HASANOV M, Milton DR, Bea Davies A, Sirmans E, et al
    Changes In Outcomes And Factors Associated With Survival In Melanoma Patients With Brain Metastases.
    Neuro Oncol. 2022 Dec 13:noac251. doi: 10.1093.
    PubMed     Abstract available


  176. HUNTOON K, Anderson SK, Ballman KV, Twohy E, et al
    Association of Circulating Markers with Cognitive Decline After Radiation Therapy for Brain Metastasis.
    Neuro Oncol. 2022 Dec 6:noac262. doi: 10.1093.
    PubMed     Abstract available


  177. MORENO V, Sepulveda JM, Reardon DA, Perez-Nunez A, et al
    Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study.
    Neuro Oncol. 2022 Dec 1:noac263. doi: 10.1093.
    PubMed     Abstract available


  178. WANG C, Zhang H, Fan J, Li Q, et al
    Inhibition of integrated stress response protects against lipid-induced senescence in hypothalamic neural stem cells in adamantinomatous craniopharyngioma.
    Neuro Oncol. 2022 Dec 1:noac261. doi: 10.1093.
    PubMed     Abstract available


    November 2022
  179. GONZALEZ CASTRO LN, Liu I, Filbin M
    Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
    Neuro Oncol. 2022 Nov 29:noac257. doi: 10.1093.
    PubMed    


  180. PRINS RM, Everson RG
    Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.".
    Neuro Oncol. 2022 Nov 29:noac256. doi: 10.1093.
    PubMed    


  181. GERRITSEN JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, et al
    Impact of maximal extent of resection on postoperative deficits, patient functioning and survival within clinically important glioblastoma subgroups.
    Neuro Oncol. 2022 Nov 24:noac255. doi: 10.1093.
    PubMed     Abstract available


  182. LIN B, Ziebro J, Smithberger E, Skinner KR, et al
    Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma.
    Neuro Oncol. 2022 Nov 23:noac254. doi: 10.1093.
    PubMed    


  183. DEAN JA, Tanguturi SK, Cagney D, Shin KY, et al
    Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.
    Neuro Oncol. 2022 Nov 19:noac253. doi: 10.1093.
    PubMed     Abstract available


  184. ZHANG IY, Liu S, Zhang L, Liang R, et al
    RAGE Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression.
    Neuro Oncol. 2022 Nov 17. pii: 6832182. doi: 10.1093.
    PubMed     Abstract available


  185. FORRY S, Hubbard L, Espey MG, Vikram B, et al
    The NCI Glioblastoma Therapeutics Network (GTN).
    Neuro Oncol. 2022 Nov 11. pii: 6822421. doi: 10.1093.
    PubMed    


  186. GIRARDI F, Matz M, Stiller C, You H, et al
    Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).
    Neuro Oncol. 2022 Nov 10. pii: 6819785. doi: 10.1093.
    PubMed     Abstract available



  187. Corrigendum to: Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
    Neuro Oncol. 2022 Nov 8. pii: 6809298. doi: 10.1093.
    PubMed    


  188. CHEN L, Xie X, Wang T, Xu L, et al
    ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling.
    Neuro Oncol. 2022 Nov 2. pii: 6794117. doi: 10.1093.
    PubMed     Abstract available


  189. SMITH K, Nakaji P, Thomas T, Pinnaduwage D, et al
    Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  190. MCCRACKEN DJ, Schupper AJ, Lakomkin N, Malcolm J, et al
    Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  191. ODIA Y, Gutierrez AN, Kotecha R
    Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  192. SCHUPPER AJ, Chanenchuk T, Racanelli A, Price G, et al
    Laser hyperthermia: Past, present, and future.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  193. WU A, Wu JY, Lim M
    Updates in intraoperative strategies for enhancing intra-axial brain tumor control.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  194. HADDAD AF, Aghi MK, Butowski N
    Novel intraoperative strategies for enhancing tumor control: Future directions.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  195. HOOGENDIJK R, van der Lugt J, Hoving E, Kremer L, et al
    The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System: Implications for cancer registries.
    Neuro Oncol. 2022;24:1811-1814.
    PubMed    


  196. GALLDIKS N, Langen KJ, Albert NL, Law I, et al
    Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.
    Neuro Oncol. 2022;24:1815-1826.
    PubMed     Abstract available


  197. YEO KK, MacDonald SM
    CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past.
    Neuro Oncol. 2022;24:1962-1963.
    PubMed    


  198. FONSECA A, Faure-Conter C, Murray MJ, Fangusaro J, et al
    Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials.
    Neuro Oncol. 2022;24:1950-1961.
    PubMed     Abstract available


    October 2022
  199. NAKATA S, Murai J, Okada M, Takahashi H, et al
    Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin.
    Neuro Oncol. 2022 Oct 23. pii: 6770101. doi: 10.1093.
    PubMed     Abstract available


  200. ZHAO J, Yang S, Cui X, Wang Q, et al
    A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Neuro Oncol. 2022 Oct 22. pii: 6770036. doi: 10.1093.
    PubMed     Abstract available


  201. KOEKKOEK JAF, van der Meer PB, Pace A, Hertler C, et al
    Palliative care and end-of-life care in adults with malignant brain tumors.
    Neuro Oncol. 2022 Oct 22. pii: 6769915. doi: 10.1093.
    PubMed     Abstract available


  202. SHORT SC
    EV packing allows meningioma tracking in blood.
    Neuro Oncol. 2022 Oct 21. pii: 6765271. doi: 10.1093.
    PubMed    


  203. RUDA R
    Optimize Treatment Approaches In Isocitrate Dehydrogenase (Idh) Mutant Gliomas: Open Issues.
    Neuro Oncol. 2022 Oct 17. pii: 6761819. doi: 10.1093.
    PubMed    


  204. CHANG G, Xie GS, Ma L, Li P, et al
    USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
    Neuro Oncol. 2022 Oct 14. pii: 6761025. doi: 10.1093.
    PubMed     Abstract available


  205. GREEN K, Panagopoulou P, D'Arco F, O'Hare P, et al
    A Nationwide Evaluation of Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK: Safety. Efficacy, Visual Morbidity and Outcomes.
    Neuro Oncol. 2022 Oct 14. pii: 6761018. doi: 10.1093.
    PubMed     Abstract available


  206. AWADA H, Paris F, Pecqueur C
    Exploiting Radiation Immunostimulatory Effects To Improve Glioblastoma Outcome.
    Neuro Oncol. 2022 Oct 14. pii: 6761020. doi: 10.1093.
    PubMed     Abstract available


  207. CHOUDHURY A, Chen WC, Lucas CG, Bayley JC, et al
    Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.
    Neuro Oncol. 2022 Oct 13. pii: 6760303. doi: 10.1093.
    PubMed     Abstract available


  208. MILLER JJ, Gonzalez Castro LN, McBrayer S, Weller M, et al
    Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
    Neuro Oncol. 2022 Oct 12. pii: 6761148. doi: 10.1093.
    PubMed     Abstract available


  209. KOROVINA I, Vehlow A, Temme A, Cordes N, et al
    Targeting integrin alpha2 as potential strategy for radiochemosensitization of glioblastoma.
    Neuro Oncol. 2022 Oct 11. pii: 6758417. doi: 10.1093.
    PubMed     Abstract available


  210. SCHAKELAAR MY, Monnikhof M, Crnko S, Pijnappel E, et al
    Cellular Immunotherapy for Medulloblastoma.
    Neuro Oncol. 2022 Oct 11. pii: 6758415. doi: 10.1093.
    PubMed     Abstract available


  211. WOLLRING MM, Werner JM, Bauer EK, Tscherpel C, et al
    Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Neuro Oncol. 2022 Oct 10. pii: 6755441. doi: 10.1093.
    PubMed     Abstract available


  212. YANG R, Zhang G, Dong Z, Wang S, et al
    HOXA3 and KDM6A cooperate in transcriptional control of aerobic glycolysis and glioblastoma progression.
    Neuro Oncol. 2022 Oct 10. pii: 6755443. doi: 10.1093.
    PubMed     Abstract available


  213. GIRARDI F, Di Carlo V, Stiller C, Gatta G, et al
    Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3).
    Neuro Oncol. 2022 Oct 10. pii: 6755369. doi: 10.1093.
    PubMed     Abstract available


  214. GONZALEZ CASTRO LN, Liu I, Filbin M
    Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
    Neuro Oncol. 2022 Oct 5. pii: 6748723. doi: 10.1093.
    PubMed     Abstract available


  215. OSTROM QT, Price M, Neff C, Cioffi G, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  216. KUMTHEKAR P, Nagpal S
    Preclinical modeling in leptomeningeal disease: Starting at the foundation to tackle a difficult disease.
    Neuro Oncol. 2022;24:1687-1688.
    PubMed    


  217. LUKAS RV
    Leptomeningeal metastases-What outcomes should we measure and how?
    Neuro Oncol. 2022;24:1736-1737.
    PubMed    


  218. BOCKMAYR M, Harnisch K, Pohl LC, Schweizer L, et al
    Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.
    Neuro Oncol. 2022;24:1689-1699.
    PubMed     Abstract available


  219. LAW V, Chen Z, Vena F, Smalley I, et al
    A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
    Neuro Oncol. 2022;24:1673-1686.
    PubMed     Abstract available


  220. LE RHUN E, Devos P, Winklhofer S, Lmalem H, et al
    Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
    Neuro Oncol. 2022;24:1726-1735.
    PubMed     Abstract available


    September 2022
  221. LIN B, Ziebro J, Smithberger E, Skinner KR, et al
    EGFR, the Lazarus target for precision oncology in glioblastoma.
    Neuro Oncol. 2022 Sep 19. pii: 6705404. doi: 10.1093.
    PubMed     Abstract available


  222. HOFFMAN LM, Jaimes C, Mankad K, Mirsky DM, et al
    Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
    Neuro Oncol. 2022 Sep 17. pii: 6702540. doi: 10.1093.
    PubMed     Abstract available


  223. KASHANI E, Schnidrig D, Hashemi Gheinani A, Ninck MS, et al
    Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-beta signaling in recurrent tumors.
    Neuro Oncol. 2022 Sep 17. pii: 6702539. doi: 10.1093.
    PubMed     Abstract available


  224. OSTROM QT, Price M, Ryan K, Edelson J, et al
    CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Neuro Oncol. 2022;24.
    PubMed     Abstract available


  225. STEJEREAN-TODORAN I, Gimotty PA, Watters A, Brafford P, et al
    A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
    Neuro Oncol. 2022 Sep 2. pii: 6687782. doi: 10.1093.
    PubMed     Abstract available


  226. INDELICATO DJ
    No question: Proton therapy is safe.
    Neuro Oncol. 2022;24:1582-1583.
    PubMed    


    August 2022
  227. YU K, Kong K, Lozzi B, Luna-Figueroa E, et al
    In Vivo Functional Characterization of EGFR Variants Identifies Novel Drivers of Glioblastoma.
    Neuro Oncol. 2022 Aug 31. pii: 6679484. doi: 10.1093.
    PubMed     Abstract available


  228. BEDDOK A, Scher N, Alapetite C, Baussart B, et al
    Protontherapy for adult craniopharyngioma: experience of a single institution in 91 consecutive patients.
    Neuro Oncol. 2022 Aug 25. pii: 6674791. doi: 10.1093.
    PubMed     Abstract available


  229. OSTROM QT, Shoaf ML, Cioffi G, Waite K, et al
    National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Neuro Oncol. 2022 Aug 22. pii: 6673397. doi: 10.1093.
    PubMed     Abstract available


  230. YOUNGBLOOD MW, Tran AN, Wang W, An S, et al
    Docetaxel Targets Aggressive Methylation Profiles and Serves as a Radiosensitizer in High-Risk Meningiomas.
    Neuro Oncol. 2022 Aug 17. pii: 6670614. doi: 10.1093.
    PubMed     Abstract available


  231. SHI DD, Youssef GC, Nassar AH, Lim-Fat MJ, et al
    Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2022 Aug 16. pii: 6668736. doi: 10.1093.
    PubMed    


  232. VAN OPIJNEN MP, Tesileanu CMS, Dirven L, van der Meer PB, et al
    IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
    Neuro Oncol. 2022 Aug 16. pii: 6668487. doi: 10.1093.
    PubMed     Abstract available


  233. KARSCHNIA P, Young JS, Dono A, Hani L, et al
    Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group.
    Neuro Oncol. 2022 Aug 12. pii: 6664041. doi: 10.1093.
    PubMed     Abstract available


  234. SEYVE A, Dehais C, Chinot O, Djelad A, et al
    Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study.
    Neuro Oncol. 2022 Aug 12. pii: 6661438. doi: 10.1093.
    PubMed     Abstract available


  235. LUO X, Yang Y, Yin S, Li H, et al
    False-negative and false-positive outcomes of computer aided detection on brain metastasis: secondary analysis of a multicenter, multireader study.
    Neuro Oncol. 2022 Aug 9. pii: 6658946. doi: 10.1093.
    PubMed     Abstract available


  236. RUDA R, Capper D, Waldman AD, Pallud J, et al
    Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors.
    Neuro Oncol. 2022 Aug 1. pii: 6652587. doi: 10.1093.
    PubMed     Abstract available


  237. BOELE FW, den Otter PWM, Reijneveld JC, de Witt Hamer PC, et al
    Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades.
    Neuro Oncol. 2022 Aug 1. pii: 6652588. doi: 10.1093.
    PubMed     Abstract available


  238. VARADHARAJAN S, Mack SC
    Leveraging epigenomic patterns to resolve the heterogeneity and origins of CNS germ cell tumors.
    Neuro Oncol. 2022;24:1259-1260.
    PubMed    


  239. DESJARDINS A
    Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity.
    Neuro Oncol. 2022;24:1350-1351.
    PubMed    


  240. YAO H, Xie W, Dai Y, Liu Y, et al
    TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
    Neuro Oncol. 2022;24:1286-1297.
    PubMed     Abstract available


  241. TAKAMI H, Elzawahry A, Mamatjan Y, Fukushima S, et al
    Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.
    Neuro Oncol. 2022;24:1246-1258.
    PubMed     Abstract available


  242. KOH KN, Wong RX, Lee DE, Han JW, et al
    Outcomes of intracranial germinoma-A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies.
    Neuro Oncol. 2022;24:1389-1399.
    PubMed     Abstract available


    July 2022
  243. HERTLER C, Seystahl K, Le Rhun E, Wirsching HG, et al
    Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.
    Neuro Oncol. 2022 Jul 30. pii: 6652283. doi: 10.1093.
    PubMed    



  244. Erratum to: Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2022 Jul 29. pii: 6651886. doi: 10.1093.
    PubMed    


  245. CHEN AT, Xiao Y, Tang X, Baqri M, et al
    Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.
    Neuro Oncol. 2022 Jul 28. pii: 6651351. doi: 10.1093.
    PubMed     Abstract available


  246. SIGAUD R, Rosch L, Gatzweiler C, Benzel J, et al
    The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.
    Neuro Oncol. 2022 Jul 27. pii: 6650335. doi: 10.1093.
    PubMed     Abstract available


  247. DREXLER R, Schuller U, Eckhardt A, Filipski K, et al
    DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
    Neuro Oncol. 2022 Jul 22. pii: 6648783. doi: 10.1093.
    PubMed     Abstract available


  248. WALSH KM, Neff C, Bondy ML, Kruchko C, et al
    Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
    Neuro Oncol. 2022 Jul 22. pii: 6648782. doi: 10.1093.
    PubMed     Abstract available


  249. KOSTI A, Chiou J, Guardia GDA, Lei X, et al
    ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics.
    Neuro Oncol. 2022 Jul 21. pii: 6648020. doi: 10.1093.
    PubMed     Abstract available


  250. LASSMAN AB, Pugh SL, Wang TJC, Aldape K, et al
    Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.
    Neuro Oncol. 2022 Jul 15. pii: 6645128. doi: 10.1093.
    PubMed     Abstract available


  251. BUEHLER M, Yi X, Ge W, Blattmann P, et al
    Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions.
    Neuro Oncol. 2022 Jul 8. pii: 6634186. doi: 10.1093.
    PubMed     Abstract available


  252. REYES-GONZALEZ J, Barajas-Olmos F, Garcia-Ortiz H, Magraner-Pardo L, et al
    Brain Radiotoxicity-Related 15CAcBRT Gene Expression Signature Predicts Survival Prognosis of Glioblastoma Patients.
    Neuro Oncol. 2022 Jul 8. pii: 6634161. doi: 10.1093.
    PubMed     Abstract available


  253. VAN DER VOORT SR, Incekara F, Wijnenga MMJ, Kapsas G, et al
    Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning.
    Neuro Oncol. 2022 Jul 5. pii: 6631283. doi: 10.1093.
    PubMed     Abstract available


  254. HUSE JT
    A Promising Preclinical Model For Tert Promoter Mutation In Glioblastoma.
    Neuro Oncol. 2022 Jul 3. pii: 6628220. doi: 10.1093.
    PubMed    


  255. DONAHUE BR, MacDonald S
    Protons for pediatric ependymoma: Where are we now?
    Neuro Oncol. 2022;24:1203-1204.
    PubMed    


  256. MILLWARD CP, Armstrong TS, Barrington H, Brodbelt AR, et al
    Opportunities and challenges for the development of "core outcome sets" in neuro-oncology.
    Neuro Oncol. 2022;24:1048-1055.
    PubMed     Abstract available


  257. HERRGOTT GA, Asmaro KP, Wells M, Sabedot TS, et al
    Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Neuro Oncol. 2022;24:1126-1139.
    PubMed     Abstract available


  258. PETERS S, Merta J, Schmidt L, Jazmati D, et al
    Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study.
    Neuro Oncol. 2022;24:1193-1202.
    PubMed     Abstract available


    June 2022
  259. PALMER JD, Prasad RN, Cioffi G, Kruchtko C, et al
    Exposure to Radon and Heavy Particulate Pollution and Incidence of Brain Tumors.
    Neuro Oncol. 2022 Jun 28. pii: 6618967. doi: 10.1093.
    PubMed     Abstract available


  260. AIZER AA, Lamba N, Ahluwalia MS, Aldape K, et al
    Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
    Neuro Oncol. 2022 Jun 28. pii: 6618874. doi: 10.1093.
    PubMed     Abstract available


  261. NOBRE L, Bouffet E
    BRAF inhibitors in BRAFV600E mutated pediatric high-grade gliomas: upfront or at recurrence?
    Neuro Oncol. 2022 Jun 24. pii: 6617660. doi: 10.1093.
    PubMed    


  262. WEISHAUPT H, Cancer M, Rosen G, Holmberg KO, et al
    Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
    Neuro Oncol. 2022 Jun 23. pii: 6615415. doi: 10.1093.
    PubMed     Abstract available


  263. CHEN X, Niu W, Fan X, Yang H, et al
    Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells.
    Neuro Oncol. 2022 Jun 21. pii: 6612239. doi: 10.1093.
    PubMed     Abstract available


  264. WANG Y, Wang K, Fu J, Zhang Y, et al
    FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1.
    Neuro Oncol. 2022 Jun 20. pii: 6611687. doi: 10.1093.
    PubMed     Abstract available


  265. NATSUME A, Arakawa Y, Narita Y, Sugiyama K, et al
    The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
    Neuro Oncol. 2022 Jun 20. pii: 6611503. doi: 10.1093.
    PubMed     Abstract available


  266. LIU XP, Jin X, Ahmadian SS, Yang X, et al
    Clinical Significance and Molecular Annotation of Cellular Morphometric Subtypes in Lower Grade Gliomas discovered by Machine Learning.
    Neuro Oncol. 2022 Jun 18. pii: 6611075. doi: 10.1093.
    PubMed     Abstract available


  267. OSTROM QT, Lu D, Lu R, Baker MC, et al
    Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.
    Neuro Oncol. 2022 Jun 17. pii: 6609733. doi: 10.1093.
    PubMed    


  268. SARAF A, Yock TI, Niemierko A, Oh KS, et al
    Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience.
    Neuro Oncol. 2022 Jun 7. pii: 6603917. doi: 10.1093.
    PubMed     Abstract available


  269. LEE-CHANG C
    Understanding the relationship between gliomas and T cells: Paving the way for effective immunotherapy.
    Neuro Oncol. 2022 Jun 6. pii: 6602133. doi: 10.1093.
    PubMed    


  270. ROGERS CL, Pugh SL, Vogelbaum MA, Perry A, et al
    Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539.
    Neuro Oncol. 2022 Jun 3. pii: 6601387. doi: 10.1093.
    PubMed     Abstract available


  271. TAYLOR JW, Weyer-Jamora C, Hervey-Jumper S
    Molecularly determining cognition in glioma: New insights as the plot thickens.
    Neuro Oncol. 2022 Jun 3. pii: 6601533. doi: 10.1093.
    PubMed    


  272. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Standardizing reporting of brain and central nervous system tumors in the United Kingdom.
    Neuro Oncol. 2022;24:1032-1033.
    PubMed    


  273. MANGUM R, Parsons DW
    TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions.
    Neuro Oncol. 2022;24:1008-1009.
    PubMed    


  274. FAROUK SAIT S, Karajannis MA
    Chemotherapy plus focal radiation therapy for localized intracranial germinoma: How little is enough?
    Neuro Oncol. 2022;24:984-985.
    PubMed    


  275. CAI F, Chen S, Yu X, Zhang J, et al
    Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes.
    Neuro Oncol. 2022;24:925-935.
    PubMed     Abstract available


  276. BARTELS U, Onar-Thomas A, Patel SK, Shaw D, et al
    Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
    Neuro Oncol. 2022;24:974-983.
    PubMed     Abstract available


  277. PARK AK, Waheed A, Forst DA, Al-Samkari H, et al
    Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.
    Neuro Oncol. 2022;24:964-973.
    PubMed     Abstract available


    May 2022

  278. Erratum to: Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2022 May 27. pii: 6594729. doi: 10.1093.
    PubMed    


  279. NOBRE L, Hawkins C
    Liquid biopsy for pediatric brain tumor patients: is it prime time yet?
    Neuro Oncol. 2022 May 27. pii: 6593987. doi: 10.1093.
    PubMed    


  280. VERPLOEGH ISC, Conidi A, Brouwer RWW, Balcioglu HE, et al
    Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers.
    Neuro Oncol. 2022 May 26. pii: 6593858. doi: 10.1093.
    PubMed     Abstract available


  281. DE LA FUENTE MI, Colman H, Rosenthal M, Van Tine BA, et al
    Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
    Neuro Oncol. 2022 May 25. pii: 6593129. doi: 10.1093.
    PubMed     Abstract available


  282. FRIEDRICH M, Hahn M, Michel J, Sankowski R, et al
    Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
    Neuro Oncol. 2022 May 24. pii: 6591514. doi: 10.1093.
    PubMed     Abstract available


  283. GRIGUOLO G, Tosi A, Dieci MV, Fineberg S, et al
    A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.
    Neuro Oncol. 2022 May 24. pii: 6591493. doi: 10.1093.
    PubMed     Abstract available


  284. MESSINGER D, Harris MK, Cummings JR, Thomas C, et al
    Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
    Neuro Oncol. 2022 May 23. pii: 6590903. doi: 10.1093.
    PubMed     Abstract available


  285. YEO KK, Alexandrescu S, Cotter JA, Vogelzang J, et al
    Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics.
    Neuro Oncol. 2022 May 23. pii: 6590765. doi: 10.1093.
    PubMed     Abstract available


  286. GIRARDI F, Coleman MP, Allemani C
    Reply to "Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al".
    Neuro Oncol. 2022 May 21. pii: 6590321. doi: 10.1093.
    PubMed    


  287. HOOGENDIJK R, van der Lugt J, van Vuurden DG, Visser O, et al
    Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al.
    Neuro Oncol. 2022 May 21. pii: 6590318. doi: 10.1093.
    PubMed    


  288. EDMONSTON DY, Wu S, Li Y, Khan RB, et al
    Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 May 12. pii: 6585053. doi: 10.1093.
    PubMed     Abstract available


  289. SAMPETREAN O, Saya H
    What can metabolites tell us about gliomas?
    Neuro Oncol. 2022 May 12. pii: 6584800. doi: 10.1093.
    PubMed    


  290. BARTLETT A, Lane A, Chaney B, Escorza NY, et al
    Characteristics of Children
    Neuro Oncol. 2022 May 12. pii: 6585024. doi: 10.1093.
    PubMed     Abstract available


  291. RICKLEFS FL, Maire CL, Wollmann K, Duhrsen L, et al
    Diagnostic potential of extracellular vesicles in meningioma patients.
    Neuro Oncol. 2022 May 12. pii: 6585054. doi: 10.1093.
    PubMed     Abstract available


  292. REED-GUY L, Desai AS, Phillips RE, Croteau D, et al
    Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Neuro Oncol. 2022 May 12. pii: 6585055. doi: 10.1093.
    PubMed     Abstract available


  293. ROESLER R, de Farias CB, Brunetto AT, Gregianin L, et al
    Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Neuro Oncol. 2022 May 11. pii: 6584501. doi: 10.1093.
    PubMed    



  294. Erratum to: path-03. Ferroptosis-related long non-coding rna signatures predict prognosis in patients with glioma.
    Neuro Oncol. 2022 May 9. pii: 6583332. doi: 10.1093.
    PubMed    


  295. WINKLER F
    Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.
    Neuro Oncol. 2022 May 9. pii: 6582767. doi: 10.1093.
    PubMed    


  296. GALLDIKS N, Lohmann P, Langen KJ
    The role of 11C-methionine PET in patients with newly diagnosed WHO grade 2 or 3 gliomas.
    Neuro Oncol. 2022 May 5. pii: 6581471. doi: 10.1093.
    PubMed    


  297. CASES-CUNILLERA S, van Loo KMJ, Pitsch J, Quatraccioni A, et al
    Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.
    Neuro Oncol. 2022;24:741-754.
    PubMed     Abstract available


  298. SATOMI K, Takami H, Fukushima S, Yamashita S, et al
    12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:834-846.
    PubMed     Abstract available


  299. LAZOW MA, Fuller C, DeWire M, Lane A, et al
    Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
    Neuro Oncol. 2022;24:821-833.
    PubMed     Abstract available


  300. RUDA R, Bruno F, Ius T, Silvani A, et al
    IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.
    Neuro Oncol. 2022;24:809-820.
    PubMed     Abstract available


  301. FELIX M, Friedel D, Jayavelu AK, Filipski K, et al
    HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Neuro Oncol. 2022 May 3. pii: 6578556. doi: 10.1093.
    PubMed     Abstract available


  302. RICKLEFS FL, Drexler R, Wollmann K, Eckhardt A, et al
    DNA Methylation subclass Receptor Tyrosine Kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
    Neuro Oncol. 2022 May 2. pii: 6577052. doi: 10.1093.
    PubMed     Abstract available


  303. LIM M, Weller M, Idbaih A, Steinbach J, et al
    Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.
    Neuro Oncol. 2022 May 2. pii: 6577049. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  304. PERSSON ML, Douglas AM, Alvaro F, Faridi P, et al
    The intrinsic and microenvironmental features of diffuse midline glioma; implications for the development of effective immunotherapeutic treatment strategies.
    Neuro Oncol. 2022 Apr 27. pii: 6575144. doi: 10.1093.
    PubMed     Abstract available


  305. MERCHANT TE, Edmonston DY, Wu S, Li Y, et al
    Endocrine Outcomes after Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 Apr 27. pii: 6575137. doi: 10.1093.
    PubMed     Abstract available


  306. DING J, Li X, Khan S, Zhang C, et al
    EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
    Neuro Oncol. 2022 Apr 26. pii: 6574563. doi: 10.1093.
    PubMed     Abstract available


  307. GUTIERREZ-VALENCIA E, Kalyvas A, Villafuerte CJ, Millar BA, et al
    Factors Correlating with Survival Following Adjuvant or Definitive Radiosurgery for Large Brain Metastases.
    Neuro Oncol. 2022 Apr 26. pii: 6574580. doi: 10.1093.
    PubMed     Abstract available


  308. JAIN B, Dee EC, Jain U, Aizer AA, et al
    Trends in location of death for individuals with primary brain tumors in the United States.
    Neuro Oncol. 2022 Apr 26. pii: 6574444. doi: 10.1093.
    PubMed    


  309. SCHONROCK A, Heinzelmann E, Steffl B, Demirdizen E, et al
    MEOX2 homeobox gene promotes growth of malignant gliomas.
    Neuro Oncol. 2022 Apr 25. pii: 6573906. doi: 10.1093.
    PubMed     Abstract available


  310. MA R, Rei M, Woodhouse I, Ferris K, et al
    Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.
    Neuro Oncol. 2022 Apr 25. pii: 6573935. doi: 10.1093.
    PubMed     Abstract available


  311. MINAMI N, Hong D, Stevers N, Barger CJ, et al
    Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.
    Neuro Oncol. 2022 Apr 23. pii: 6573305. doi: 10.1093.
    PubMed     Abstract available


  312. IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
    Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.
    Neuro Oncol. 2022 Apr 23. pii: 6573306. doi: 10.1093.
    PubMed     Abstract available


  313. CHUNG C, Brown PD, Wefel JS
    Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial.
    Neuro Oncol. 2022 Apr 23. pii: 6573235. doi: 10.1093.
    PubMed    


  314. PUROW B
    ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma.
    Neuro Oncol. 2022 Apr 23. pii: 6573255. doi: 10.1093.
    PubMed    


  315. OMURO A, Brandes AA, Carpentier AF, Idbaih A, et al
    Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
    Neuro Oncol. 2022 Apr 14. pii: 6568419. doi: 10.1093.
    PubMed     Abstract available


  316. COUTURIER CP, Nadaf J, Li Z, Baig S, et al
    Glioblastoma scRNAseq Shows Treatment-induced, Immune-dependent Rise In Mesenchymal Cancer Cells, and Structural Variants in Distal Neural Stem Cells.
    Neuro Oncol. 2022 Apr 13. pii: 6567757. doi: 10.1093.
    PubMed     Abstract available


  317. COOMANS M, Dirven L, Aaronson N, Baumert BG, et al
    Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
    Neuro Oncol. 2022 Apr 11. pii: 6566436. doi: 10.1093.
    PubMed     Abstract available


  318. GHOSH S
    Breaking the DLG shackles in glioblastoma.
    Neuro Oncol. 2022 Apr 11. pii: 6566243. doi: 10.1093.
    PubMed    


  319. ROSENBERG T, Yeo KK, Mauguen A, Alexandrescu S, et al
    Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566011. doi: 10.1093.
    PubMed     Abstract available


  320. ZHANG L, Nesvick CL, Day CA, Choi J, et al
    STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566009. doi: 10.1093.
    PubMed     Abstract available


  321. KANMOUNYE US, Karekezi C, Nyalundja AD, Awad AK, et al
    Adult brain tumors in Sub-Saharan Africa: A scoping review.
    Neuro Oncol. 2022 Apr 9. pii: 6566010. doi: 10.1093.
    PubMed     Abstract available


  322. ZHANG Y, Lucas CG, Young JS, Morshed RA, et al
    Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.
    Neuro Oncol. 2022 Apr 8. pii: 6565639. doi: 10.1093.
    PubMed     Abstract available


  323. BIEGEL JA
    Meeting the high expectations for liquid biopsy assays for pediatric brain tumors: progress and challenges.
    Neuro Oncol. 2022 Apr 5. pii: 6563880. doi: 10.1093.
    PubMed    


  324. ELLINGSON BM, Gerstner ER, Lassman AB, Chung C, et al
    Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.
    Neuro Oncol. 2022 Apr 5. pii: 6563738. doi: 10.1093.
    PubMed     Abstract available


  325. TESILEANU CMS, Gorlia T, Golfinopoulos V, French PJ, et al
    MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
    Neuro Oncol. 2022;24:665-667.
    PubMed    


  326. FRAPPAZ D, Dhall G, Murray MJ, Goldman S, et al
    EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults.
    Neuro Oncol. 2022;24:516-527.
    PubMed     Abstract available


  327. NAKAMURA H, Takami H, Yanagisawa T, Kumabe T, et al
    The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:503-515.
    PubMed     Abstract available


  328. WU Z, Abdullaev Z, Pratt D, Chung HJ, et al
    Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics.
    Neuro Oncol. 2022;24:571-581.
    PubMed     Abstract available


    March 2022
  329. SARAN F, Eisenstat DD
    The relapse doesn't fall far from the radiotherapy field: Lessons to be learned for the future of radiotherapy in medulloblastoma from the relapse patterns of SJMB03.
    Neuro Oncol. 2022 Mar 24. pii: 6553345. doi: 10.1093.
    PubMed    


  330. PIOTROWSKI AF, Jackson S
    Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
    Neuro Oncol. 2022 Mar 23. pii: 6553267. doi: 10.1093.
    PubMed    


  331. CORDELL EC, Alghamri MS, Castro MG, Gutmann DH, et al
    T lymphocytes as dynamic regulators of glioma pathobiology.
    Neuro Oncol. 2022 Mar 23. pii: 6553145. doi: 10.1093.
    PubMed     Abstract available


  332. OSUKA S
    Targeting adaptive radioresistance in Glioblastoma.
    Neuro Oncol. 2022 Mar 22. pii: 6552309. doi: 10.1093.
    PubMed    


  333. BLOBNER J, Tonn JC
    Resection of glioma - Feeding the beast?
    Neuro Oncol. 2022 Mar 22. pii: 6552311. doi: 10.1093.
    PubMed    


  334. AZAD TD, Bettegowda C
    Longitudinal monitoring of diffuse midline glioma using liquid biopsy.
    Neuro Oncol. 2022 Mar 22. pii: 6552310. doi: 10.1093.
    PubMed    


  335. LE RHUN E, Oppong FB, Vanlancker M, Stupp R, et al
    Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
    Neuro Oncol. 2022 Mar 21. pii: 6551573. doi: 10.1093.
    PubMed     Abstract available


  336. ZHAN Q, Yi K, Cui X, Li X, et al
    Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy.
    Neuro Oncol. 2022 Mar 21. pii: 6551550. doi: 10.1093.
    PubMed     Abstract available


  337. QIN N, Paisana E, Langini M, Picard D, et al
    Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
    Neuro Oncol. 2022 Mar 21. pii: 6551011. doi: 10.1093.
    PubMed     Abstract available


  338. FANGUSARO JR, Onar-Thomas A, Poussaint TY, Wu S, et al
    Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
    Neuro Oncol. 2022 Mar 21. pii: 6551018. doi: 10.1093.
    PubMed    


  339. FERDOSI SR, Taylor B, Lee M, Tang N, et al
    PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
    Neuro Oncol. 2022 Mar 19. pii: 6550856. doi: 10.1093.
    PubMed     Abstract available


  340. BOUFFET E, Lafay-Cousin L
    Infant brain tumor trials: Beyond feasibility.
    Neuro Oncol. 2022 Mar 14. pii: 6548388. doi: 10.1093.
    PubMed    


  341. ZHOU Y, Meng X, He W, Li XY, et al
    USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion.
    Neuro Oncol. 2022 Mar 14. pii: 6548387. doi: 10.1093.
    PubMed     Abstract available


  342. MOHAMED E, Kumar A, Zhang Y, Wang AS, et al
    PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Neuro Oncol. 2022 Mar 14. pii: 6548389. doi: 10.1093.
    PubMed     Abstract available


  343. FOREMAN NK
    Outcomes after first relapse of children with intracranial ependymoma treated on the second l'Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) protocol.
    Neuro Oncol. 2022;24:480-481.
    PubMed    


  344. MILLER JJ, Wang N
    Body imaging for newly diagnosed CNS lymphoma: Evaluating the utility of the evaluation.
    Neuro Oncol. 2022;24:492-493.
    PubMed    


  345. MASSIMINO M, Barretta F, Modena P, Johann P, et al
    Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.
    Neuro Oncol. 2022;24:467-479.
    PubMed     Abstract available


  346. BURGENSKE DM, Talele S, Pokorny JL, Mladek AC, et al
    Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
    Neuro Oncol. 2022;24:384-395.
    PubMed     Abstract available


  347. MILLER JJ, Cahill DP, Arrillaga-Romany I
    Enhancing demethylation-induced differentiation in IDH-mutant glioma.
    Neuro Oncol. 2022 Mar 3. pii: 6542042. doi: 10.1093.
    PubMed    


  348. MLADEK AC, Yan H, Tian S, Decker PA, et al
    RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.
    Neuro Oncol. 2022 Mar 1. pii: 6540482. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  349. BADODI S, Pomella N, Lim YM, Brandner S, et al
    Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
    Neuro Oncol. 2022 Feb 25. pii: 6537125. doi: 10.1093.
    PubMed     Abstract available


  350. PAPUSHA L, Zaytseva M, Panferova A, Druy A, et al
    Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
    Neuro Oncol. 2022 Feb 23. pii: 6535118. doi: 10.1093.
    PubMed    


  351. FERRARESE R, Carro MS
    Neural networks help zebrafish to step up as a model for efficient drug screening in glioblastoma.
    Neuro Oncol. 2022 Feb 19. pii: 6532496. doi: 10.1093.
    PubMed    


  352. NINATTI G, Sollini M, Bono B, Gozzi N, et al
    Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.
    Neuro Oncol. 2022 Feb 16. pii: 6529477. doi: 10.1093.
    PubMed     Abstract available


  353. UPADHYAY R, Liao K, Grosshans DR, McGovern SL, et al
    Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors.
    Neuro Oncol. 2022 Feb 14. pii: 6528473. doi: 10.1093.
    PubMed     Abstract available


  354. PRZYSTAL JM, Cosentino CC, Yadavilli S, Zhang J, et al
    Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Neuro Oncol. 2022 Feb 14. pii: 6528446. doi: 10.1093.
    PubMed     Abstract available


  355. BJORKBLOM B, Wibom C, Eriksson M, Bergenheim AT, et al
    Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
    Neuro Oncol. 2022 Feb 14. pii: 6528465. doi: 10.1093.
    PubMed     Abstract available


  356. LIU T, Zhu C, Chen X, Guan G, et al
    Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
    Neuro Oncol. 2022 Feb 11. pii: 6527229. doi: 10.1093.
    PubMed     Abstract available


  357. MILLER AM, Szalontay L, Bouvier N, Hill K, et al
    Next-generation Sequencing of Cerebrospinal Fluid for Clinical Molecular Diagnostics in Pediatric, Adolescent and Young Adult (AYA) Brain Tumor Patients.
    Neuro Oncol. 2022 Feb 11. pii: 6527231. doi: 10.1093.
    PubMed     Abstract available


  358. VAN KESSEL E, Berendsen S, Baumfalk AE, Venugopal H, et al
    Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma.
    Neuro Oncol. 2022 Feb 11. pii: 6527233. doi: 10.1093.
    PubMed     Abstract available


  359. LAZOW MA, Nievelstein MT, Lane A, Bandopadhayhay P, et al
    Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.
    Neuro Oncol. 2022 Feb 11. pii: 6527234. doi: 10.1093.
    PubMed     Abstract available


  360. REBCHUK AD, Chaharyn BM, Alam A, Hounjet CD, et al
    The Impact of Brain Invasion Criteria on the Incidence and Distribution of WHO Grade 1, 2 and 3 Meningiomas.
    Neuro Oncol. 2022 Feb 9. pii: 6525422. doi: 10.1093.
    PubMed     Abstract available


  361. JO J, van den Bent MJ, Nabors B, Wen PY, et al
    Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
    Neuro Oncol. 2022 Feb 8. pii: 6524653. doi: 10.1093.
    PubMed     Abstract available


  362. CANTOR E, Wierzbicki K, Tarapore RS, Ravi K, et al
    Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
    Neuro Oncol. 2022 Feb 6. pii: 6523277. doi: 10.1093.
    PubMed     Abstract available


    January 2022
  363. YIN S, Luo X, Yang Y, Shao Y, et al
    Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study.
    Neuro Oncol. 2022 Jan 31. pii: 6518101. doi: 10.1093.
    PubMed     Abstract available


  364. ALVAREZ-BRECKENRIDGE CA, Cahill DP, Brastianos PK
    Trabectedin for recurrent WHO grade 2 or 3 meningiomas-paving the road for new opportunities.
    Neuro Oncol. 2022 Jan 31. pii: 6518099. doi: 10.1093.
    PubMed    


  365. READ RD
    Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518098. doi: 10.1093.
    PubMed    


  366. BROWN CE, Rodriguez A, Palmer J, Ostberg JR, et al
    Off-the-shelf, Steroid Resistant, IL13Ralpha2-Specific CAR T Cells for Treatment of Glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518100. doi: 10.1093.
    PubMed     Abstract available


  367. LOWE SR, Wang CP, Brisco A, Whiting J, et al
    Surgical and Anatomic Factors Predict Development of Leptomeningeal Disease in Patients with Melanoma Brain Metastases.
    Neuro Oncol. 2022 Jan 29. pii: 6517353. doi: 10.1093.
    PubMed     Abstract available


  368. TAGLANG C, Batsios G, Mukherjee J, Tran M, et al
    Deuterium magnetic resonance spectroscopy enables non-invasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.
    Neuro Oncol. 2022 Jan 29. pii: 6517050. doi: 10.1093.
    PubMed     Abstract available


  369. GERSTNER ER
    Volumetric Measurements in Low Grade Glioma: Are we there yet?
    Neuro Oncol. 2022 Jan 28. pii: 6516793. doi: 10.1093.
    PubMed    


  370. KOEKKOEK JAF, van der Meer PB, Taphoorn MJB, Dirven L, et al
    Letter regarding "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors".
    Neuro Oncol. 2022 Jan 25. pii: 6515357. doi: 10.1093.
    PubMed    


  371. PICCA A, Desjardins C, Bihan K, Weiss N, et al
    Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
    Neuro Oncol. 2022 Jan 17. pii: 6509380. doi: 10.1093.
    PubMed    


  372. RAHMAN R, Huang RY
    Deep learning approaches to non-invasively assess molecular features of gliomas.
    Neuro Oncol. 2022 Jan 13. pii: 6507359. doi: 10.1093.
    PubMed    


  373. VOGELIUS IR, Bentzen SM
    Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial.
    Neuro Oncol. 2022 Jan 13. pii: 6506534. doi: 10.1093.
    PubMed    


  374. BECKER KN, Eisenmann KM
    New Targets in the Glioblastoma Tumor Microtube Multiverse: Emerging Roles for the TGF-beta/TSP1 Signaling Axis.
    Neuro Oncol. 2022 Jan 10. pii: 6502470. doi: 10.1093.
    PubMed    


  375. TRAN AN
    Targeting glutamine addiction in meningioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502476. doi: 10.1093.
    PubMed    


  376. ESPINOZA FI, Walker PR
    Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition.
    Neuro Oncol. 2022 Jan 10. pii: 6502489. doi: 10.1093.
    PubMed    


  377. VOGELBAUM MA
    Balancing Maximal Resection and Functional Preservation in Surgery for Low Grade Glioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502479. doi: 10.1093.
    PubMed    


  378. KOTCH C, Avery R, Getz KD, Bouffet E, et al
    Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
    Neuro Oncol. 2022 Jan 9. pii: 6501465. doi: 10.1093.
    PubMed     Abstract available


  379. MAEGAWA S, Gopalakrishnan V
    PLK inhibitors come of age in pediatric brain tumors.
    Neuro Oncol. 2022 Jan 7. pii: 6499977. doi: 10.1093.
    PubMed    


  380. SOFFIETTI R, Bettegowda C, Mellinghoff IK, Warren KE, et al
    Liquid biopsy in gliomas: a RANO review and proposals for clinical applications.
    Neuro Oncol. 2022 Jan 6. pii: 6499389. doi: 10.1093.
    PubMed     Abstract available


  381. MORTAZAVI A, Fayed I, Bachani M, Dowdy T, et al
    IDH Mutated Gliomas Promote Epileptogenesis through D-2-Hydroxyglutarate Dependent mTOR Hyperactivation.
    Neuro Oncol. 2022 Jan 5. pii: 6498134. doi: 10.1093.
    PubMed     Abstract available


  382. FURLAN JC, Wilson JR, Massicotte EM, Sahgal A, et al
    Recent advances and new discoveries in the pipeline of the treatment of primary spinal tumors and spinal metastases: a scoping review of registered clinical studies from 2000 to 2020.
    Neuro Oncol. 2022;24:1-13.
    PubMed     Abstract available


  383. JUHNKE BO, Gessi M, Gerber NU, Friedrich C, et al
    Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial.
    Neuro Oncol. 2022;24:127-137.
    PubMed     Abstract available


  384. LAMBA N, Catalano PJ, Bi WL, Wen PY, et al
    Predictors of long-term survival among patients with brain metastases.
    Neuro Oncol. 2022 Jan 4. pii: 6497420. doi: 10.1093.
    PubMed    


  385. KUNDU S, Nandhu MS, Longo SL, Longo JA, et al
    The scaffolding protein DLG5 promotes glioblastoma growth by controlling Sonic Hedgehog signaling in tumor stem cells.
    Neuro Oncol. 2022 Jan 4. pii: 6497518. doi: 10.1093.
    PubMed     Abstract available


  386. PAGES M, Rotem D, Gydush G, Reed S, et al
    Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Neuro Oncol. 2022 Jan 4. pii: 6497435. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  387. DE BILLY E, Pellegrino M, Orlando D, Pericoli G, et al
    Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    Neuro Oncol. 2021 Dec 29. pii: 6489024. doi: 10.1093.
    PubMed     Abstract available


  388. KNUDSEN AM, Halle B, Cedile O, Burton M, et al
    Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
    Neuro Oncol. 2021 Dec 29. pii: 6489042. doi: 10.1093.
    PubMed     Abstract available


  389. HU C, Wang K, Damon C, Fu Y, et al
    ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
    Neuro Oncol. 2021 Dec 24. pii: 6482823. doi: 10.1093.
    PubMed     Abstract available


  390. MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
    Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
    Neuro Oncol. 2021 Dec 22. pii: 6478897. doi: 10.1093.
    PubMed     Abstract available


  391. LEARY SES, Lindsay K, Geyer JR, Mehmet K, et al
    Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
    Neuro Oncol. 2021 Dec 22. pii: 6478443. doi: 10.1093.
    PubMed     Abstract available


  392. DESHPANDE K, Martirosian V, Nakamura BN, Iyer M, et al
    Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.
    Neuro Oncol. 2021 Dec 21. pii: 6473228. doi: 10.1093.
    PubMed     Abstract available


  393. YABO YA, Niclou SP, Golebiewska A
    Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2021 Dec 21. pii: 6472977. doi: 10.1093.
    PubMed     Abstract available


  394. GU J, Mu N, Jia B, Guo Q, et al
    Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.
    Neuro Oncol. 2021 Dec 14. pii: 6461092. doi: 10.1093.
    PubMed     Abstract available


  395. LUCAS JT, Tinkle CL, Huang J, Onar-Thomas A, et al
    Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
    Neuro Oncol. 2021 Dec 11. pii: 6459719. doi: 10.1093.
    PubMed     Abstract available


  396. LIM-FAT MJ, Youssef GC, Touat M, Iorgulescu JB, et al
    Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
    Neuro Oncol. 2021 Dec 8. pii: 6456497. doi: 10.1093.
    PubMed     Abstract available


  397. GARZIA L
    Faraway, so close: intratumoral heterogeneity of medulloblastoma subgroups.
    Neuro Oncol. 2021 Dec 4. pii: 6449209. doi: 10.1093.
    PubMed    


  398. HAGIWARA A, Oughourlian TC, Cho NS, Schlossman J, et al
    Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
    Neuro Oncol. 2021 Dec 2. pii: 6448328. doi: 10.1093.
    PubMed     Abstract available


  399. GUPTA T, Manjali JJ, Purandare N, Bagal B, et al
    Bone marrow biopsy in PCNSL: Relevant or redundant?
    Neuro Oncol. 2021;23:2117-2118.
    PubMed    


  400. MARGOLD M, Schlegel U
    Reply to letter to the editor by Gupta et al: Bone marrow biopsy in patients with PCNSL: relevant or redundant?
    Neuro Oncol. 2021;23:2119.
    PubMed    


  401. MOUDGIL-JOSHI J, Kaliaperumal C
    Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.
    Neuro Oncol. 2021;23:2120-2121.
    PubMed    


  402. ECKEL-PASSOW JE, Kitange GJ, Decker PA, Kosel ML, et al
    Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
    Neuro Oncol. 2021;23:2066-2075.
    PubMed     Abstract available


  403. MARNER L, Lundemann M, Sehested A, Nysom K, et al
    Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.
    Neuro Oncol. 2021;23:2107-2116.
    PubMed     Abstract available


    November 2021
  404. CHAREST A
    Optimizing an effective combination of the new microtubule targeting agent Lisavanbulin with standard of care therapy for glioblastoma in patient-derived xenograft pre-clinical models.
    Neuro Oncol. 2021 Nov 27. pii: 6444804. doi: 10.1093.
    PubMed    


  405. TAYLOR JW
    Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high grade glioma?
    Neuro Oncol. 2021 Nov 27. pii: 6444703. doi: 10.1093.
    PubMed    


  406. LEMAITRE AL, Herbet G, Ng S, Moritz-Gasser S, et al
    Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: a longitudinal, within-patient design study.
    Neuro Oncol. 2021 Nov 26. pii: 6444171. doi: 10.1093.
    PubMed     Abstract available


  407. ABDULLAH KG, Bird CE, Buehler JD, Gattie LC, et al
    Establishment of patient-derived organoid models of lower grade glioma.
    Neuro Oncol. 2021 Nov 26. pii: 6444299. doi: 10.1093.
    PubMed     Abstract available


  408. CHIOCCA EA, Gelb AB, Chen CC, Rao G, et al
    Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial.
    Neuro Oncol. 2021 Nov 26. pii: 6444298. doi: 10.1093.
    PubMed     Abstract available


  409. DA COSTA ROSA M, Yamashita AS, Riggins GJ
    Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.
    Neuro Oncol. 2021 Nov 26. pii: 6440681. doi: 10.1093.
    PubMed     Abstract available


  410. DE JOODE K, Taal W, Snijders TJ, Hanse M, et al
    Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium.
    Neuro Oncol. 2021 Nov 24. pii: 6437945. doi: 10.1093.
    PubMed    


  411. KIELISZEK AM, Aghaei N, Bassey-Archibong B, Singh SK, et al
    Low and steady wins the race: for melanoma-brain metastases, is prevention better than a cure?
    Neuro Oncol. 2021 Nov 24. pii: 6438512. doi: 10.1093.
    PubMed    


  412. WU J
    Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.
    Neuro Oncol. 2021 Nov 22. pii: 6433381. doi: 10.1093.
    PubMed    


  413. ALMSTEDT E, Rosen E, Gloger M, Stockgard R, et al
    Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
    Neuro Oncol. 2021 Nov 19. pii: 6432157. doi: 10.1093.
    PubMed     Abstract available


  414. NASSIRI F, Wang JZ, Au K, Barnholtz-Sloan J, et al
    Consensus core clinical data elements for meningiomas.
    Neuro Oncol. 2021 Nov 17. pii: 6430437. doi: 10.1093.
    PubMed     Abstract available


  415. BALIGA S, Gallotto S, Bajaj B, Lewy J, et al
    Decade Long Disease, Secondary Malignancy, and Brainstem Injury Outcomes in Pediatric and Young Adult Medulloblastoma Patients Treated with Proton Radiotherapy.
    Neuro Oncol. 2021 Nov 12. pii: 6425899. doi: 10.1093.
    PubMed     Abstract available


  416. KACHURI L, Walsh KM
    Long telomeres in need of a SNP: Germline contributions of telomere maintenance to glioma.
    Neuro Oncol. 2021 Nov 10. pii: 6425113. doi: 10.1093.
    PubMed    


  417. ELLINGSON BM, Kim GHJ, Brown M, Lee J, et al
    Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib.
    Neuro Oncol. 2021 Nov 9. pii: 6424025. doi: 10.1093.
    PubMed     Abstract available


  418. ARAKAKI AKS, Szulzewsky F, Gilbert MR, Gujral TS, et al
    Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  419. PRATT D, Sahm F, Aldape K
    DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  420. ARMSTRONG TS, Gilbert MR
    Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  421. PENAS-PRADO M
    Rare central nervous system tumors: the path to progress.
    Neuro Oncol. 2021;23.
    PubMed    


  422. ASA SL, Mete O
    Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies.
    Neuro Oncol. 2021;23:1803-1804.
    PubMed    


  423. CUI Y, Li C, Jiang Z, Zhang S, et al
    Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
    Neuro Oncol. 2021;23:1859-1871.
    PubMed     Abstract available


    October 2021
  424. MOLINARO AM
    External Controls to Improve on Glioblastoma Clinical Trials.
    Neuro Oncol. 2021 Oct 29. pii: 6414401. doi: 10.1093.
    PubMed    


  425. ANDREWS LJ, Thornton ZA, Saincher SS, Yao IY, et al
    Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Neuro Oncol. 2021 Oct 28. pii: 6413773. doi: 10.1093.
    PubMed     Abstract available


  426. SCHWARTZBAUM J, Harris R
    Age at diagnosis and sex interact to modify primary malignant glioma incidence and survival.
    Neuro Oncol. 2021 Oct 25. pii: 6409990. doi: 10.1093.
    PubMed    


  427. VACHHA BA, Huang RY
    BOLD Asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas.
    Neuro Oncol. 2021 Oct 25. pii: 6409977. doi: 10.1093.
    PubMed    


  428. PREUSSER M, Silvani A, Le Rhun E, Soffietti R, et al
    Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
    Neuro Oncol. 2021 Oct 21. pii: 6406919. doi: 10.1093.
    PubMed     Abstract available


  429. BARRETTE AM, Ronk H, Joshi T, Mussa Z, et al
    Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models.
    Neuro Oncol. 2021 Oct 17. pii: 6398692. doi: 10.1093.
    PubMed     Abstract available


  430. CLUCERU J, Interian Y, Phillips JJ, Molinaro AM, et al
    Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
    Neuro Oncol. 2021 Oct 15. pii: 6398212. doi: 10.1093.
    PubMed     Abstract available


  431. PANT A, Lim M
    Checkpoint blockade in recurrent meningiomas: Lessons for future management.
    Neuro Oncol. 2021 Oct 9. pii: 6385431. doi: 10.1093.
    PubMed    


  432. HOOGSTRATE Y, Ghisai SA, de Wit M, de Heer I, et al
    The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis.
    Neuro Oncol. 2021 Oct 5. pii: 6381406. doi: 10.1093.
    PubMed     Abstract available


  433. OSTROM QT, Cioffi G, Waite K, Kruchko C, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  434. STROWD RE
    Etched in Code: Revisiting glioma risk factors through the exome.
    Neuro Oncol. 2021 Oct 4. pii: 6380799. doi: 10.1093.
    PubMed    


  435. FRIEDMAN GK, Dhall G
    Potential Role of Carbon Ion Radiotherapy in Chromothripsis-induced Medulloblastoma and Other Malignancies.
    Neuro Oncol. 2021 Oct 4. pii: 6380754. doi: 10.1093.
    PubMed    


  436. WU J, Gupta R, Barreto J, Doo P, et al
    Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia.
    Neuro Oncol. 2021;23:1798-1800.
    PubMed    


  437. PERTZ M, Schlegel U
    Tracking the neurobiology of cognitive dysfunction in primary CNS lymphoma?
    Neuro Oncol. 2021;23:1623-1624.
    PubMed    


  438. MILDE T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, et al
    Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.
    Neuro Oncol. 2021;23:1634-1646.
    PubMed     Abstract available


  439. GENG H, Tsang M, Subbaraj L, Cleveland J, et al
    Tumor metabolism and neurocognition in CNS lymphoma.
    Neuro Oncol. 2021;23:1668-1679.
    PubMed     Abstract available


    September 2021
  440. DEL BENE M, Osti D, Faletti S, Beznousenko GV, et al
    Extracellular vesicles: the key for precision medicine in glioblastoma.
    Neuro Oncol. 2021 Sep 28. pii: 6377304. doi: 10.1093.
    PubMed     Abstract available


  441. RAO R, Han R, Ogurek S, Xue C, et al
    Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition.
    Neuro Oncol. 2021 Sep 25. pii: 6375369. doi: 10.1093.
    PubMed     Abstract available


  442. PENG J, Kim DD, Patel JB, Zeng X, et al
    Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.
    Neuro Oncol. 2021 Sep 22. pii: 6374130. doi: 10.1093.
    PubMed    


  443. JOSEPH JV, Magaut CR, Storevik S, Geraldo LH, et al
    TGF- promotes microtube formation in glioblastoma through Thrombospondin 1.
    Neuro Oncol. 2021 Sep 20. pii: 6372853. doi: 10.1093.
    PubMed     Abstract available


  444. LUCAS CG, Mueller S, Reddy A, Taylor JW, et al
    Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
    Neuro Oncol. 2021 Sep 14. pii: 6370137. doi: 10.1093.
    PubMed    


  445. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Sep 14. pii: 6370123. doi: 10.1093.
    PubMed    


  446. BORNHORST M
    New insights into low grade glioma tumor microenvironment for improved patient management.
    Neuro Oncol. 2021 Sep 13. pii: 6369407. doi: 10.1093.
    PubMed    


  447. ABOUNADER R, Schiff D
    The blood-brain barrier limits the therapeutic efficacy of antibody drug conjugates in glioblastoma.
    Neuro Oncol. 2021 Sep 13. pii: 6369406. doi: 10.1093.
    PubMed    


  448. ZHANG W, Talele S, Sarkaria JN, Elmquist WF, et al
    Changes in the vasculature of human brain tumors: Implications for treatment.
    Neuro Oncol. 2021 Sep 13. pii: 6369378. doi: 10.1093.
    PubMed    


  449. IJARE OB, Hambarde S, Brasil da Costa FH, Lopez S, et al
    Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.
    Neuro Oncol. 2021 Sep 13. pii: 6369334. doi: 10.1093.
    PubMed     Abstract available


  450. MAROSI C
    Will mastering ferroptosis allow treating refractory meningiomas?
    Neuro Oncol. 2021 Sep 13. pii: 6369228. doi: 10.1093.
    PubMed    


  451. DRIVER J, Hoffman SE, Tavakol S, Woodward E, et al
    A Molecularly Integrated Grade for Meningioma.
    Neuro Oncol. 2021 Sep 11. pii: 6368844. doi: 10.1093.
    PubMed     Abstract available


  452. TOM MC, Kotecha R
    Beating a Benchmark: Boron Neutron Capture Therapy for Recurrent and Refractory Meningiomas.
    Neuro Oncol. 2021 Sep 11. pii: 6368846. doi: 10.1093.
    PubMed    


  453. IUS T, Ng S, Young JS, Tomasino B, et al
    The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study.
    Neuro Oncol. 2021 Sep 8. pii: 6366593. doi: 10.1093.
    PubMed     Abstract available


  454. SAUNDERS CN, Kinnersley B, Culliford R, Cornish AJ, et al
    Relationship between genetically determined telomere length and glioma risk.
    Neuro Oncol. 2021 Sep 3. pii: 6363706. doi: 10.1093.
    PubMed     Abstract available


  455. WANG D, Veo B, Pierce A, Fosmire S, et al
    A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Neuro Oncol. 2021 Sep 3. pii: 6363671. doi: 10.1093.
    PubMed     Abstract available


  456. BANDOPADHAYAY P, Chi SN
    The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.
    Neuro Oncol. 2021 Sep 3. pii: 6363655. doi: 10.1093.
    PubMed    


  457. AQUILANTI E, Kageler L, Wen PY, Meyerson M, et al
    Telomerase as a therapeutic target in glioblastoma.
    Neuro Oncol. 2021 Sep 2. pii: 6362724. doi: 10.1093.
    PubMed     Abstract available


  458. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
    Neuro Oncol. 2021;23:1457-1469.
    PubMed     Abstract available


  459. THACKER N, Bouffet E
    Posterior fossa syndrome-time to unmute the silence on cerebellar mutism.
    Neuro Oncol. 2021;23:1427-1428.
    PubMed    


  460. VON HOFF K, Haberler C, Schmitt-Hoffner F, Schepke E, et al
    Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study.
    Neuro Oncol. 2021;23:1597-1611.
    PubMed     Abstract available


  461. KHAN RB, Patay Z, Klimo P, Huang J, et al
    Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study.
    Neuro Oncol. 2021;23:1586-1596.
    PubMed     Abstract available


    August 2021
  462. CHUNG C, Brown PD, Wefel JS
    Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al.
    Neuro Oncol. 2021 Aug 28. pii: 6359127. doi: 10.1093.
    PubMed    


  463. PRESS RH, Chhabra AM, Choi JI, Hasan S, et al
    Proton therapy for newly diagnosed glioblastoma: more room for investigation.
    Neuro Oncol. 2021 Aug 28. pii: 6359128. doi: 10.1093.
    PubMed    


  464. CICONE F, Cascini GL, Minniti G
    Reply to: "Letter to the Editor: Assessment of imaging biomarkers in the follow-up of brain metastases after SRS".
    Neuro Oncol. 2021 Aug 24. pii: 6357080. doi: 10.1093.
    PubMed    


  465. DERKS SHAE, Jongen JLM, van den Bent MJ, van der Veldt AAM, et al
    Assessment of imaging biomarkers in the follow-up of brain metastases after SRS.
    Neuro Oncol. 2021 Aug 24. pii: 6357079. doi: 10.1093.
    PubMed    


  466. RONSLEY R, Bouffet E
    COVID-19 in pediatric cancer: Where are the brain tumors?
    Neuro Oncol. 2021 Aug 20. pii: 6355395. doi: 10.1093.
    PubMed    


  467. WANG GM, Cioffi G, Patil N, Waite KA, et al
    Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
    Neuro Oncol. 2021 Aug 13. pii: 6350590. doi: 10.1093.
    PubMed     Abstract available


  468. JO J, Donahue J, Sarai G, Petroni G, et al
    Management of Venous Thromboembolism in High-Grade Glioma: Does Low Molecular Weight Heparin Increase Intracranial Bleeding Risk?
    Neuro Oncol. 2021 Aug 12. pii: 6348905. doi: 10.1093.
    PubMed     Abstract available


  469. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Erratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
    Neuro Oncol. 2021 Aug 7. pii: 6345198. doi: 10.1093.
    PubMed    


  470. LAMBA N, Aizer AA
    The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases.
    Neuro Oncol. 2021 Aug 5. pii: 6341089. doi: 10.1093.
    PubMed    


  471. WINKLER F
    Silencing glioblastoma networks to make temozolomide more effective.
    Neuro Oncol. 2021 Aug 4. pii: 6339977. doi: 10.1093.
    PubMed    


  472. SU JM, Kilburn LB, Mansur DB, Krailo M, et al
    Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
    Neuro Oncol. 2021 Aug 4. pii: 6339987. doi: 10.1093.
    PubMed     Abstract available


  473. HUANG H, Georganaki M, Conze LL, Lavina B, et al
    ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
    Neuro Oncol. 2021 Aug 4. pii: 6339962. doi: 10.1093.
    PubMed     Abstract available


  474. WEN PY, Packer RJ
    The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications.
    Neuro Oncol. 2021;23:1215-1217.
    PubMed    


  475. LOUIS DN, Perry A, Wesseling P, Brat DJ, et al
    The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
    Neuro Oncol. 2021;23:1231-1251.
    PubMed     Abstract available


  476. CORREA DD
    Neurocognitive functions in primary CNS lymphoma.
    Neuro Oncol. 2021;23:1220-1221.
    PubMed    


  477. MOSELLA MS, Sabedot TS, Silva TC, Malta TM, et al
    DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.
    Neuro Oncol. 2021;23:1292-1303.
    PubMed     Abstract available


  478. VAN DER MEULEN M, Dirven L, Habets EJJ, Bakunina K, et al
    Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
    Neuro Oncol. 2021;23:1315-1326.
    PubMed     Abstract available


    July 2021
  479. MUNOZ PINTO MF, Campbell SJ, Simoglou Karali C, Johanssen VA, et al
    Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein.
    Neuro Oncol. 2021 Jul 23. pii: 6326734. doi: 10.1093.
    PubMed     Abstract available


  480. RICHARDSON S, Hill RM, Kui C, Lindsey JC, et al
    Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
    Neuro Oncol. 2021 Jul 17. pii: 6323243. doi: 10.1093.
    PubMed     Abstract available


  481. SHIH HA
    An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.
    Neuro Oncol. 2021 Jul 16. pii: 6323026. doi: 10.1093.
    PubMed    


  482. HULSBERGEN AFC, Abunimer AM, Ida F, Kavouridis VK, et al
    Neurosurgical resection for locally recurrent brain metastasis.
    Neuro Oncol. 2021 Jul 16. pii: 6322695. doi: 10.1093.
    PubMed     Abstract available


  483. SHARMA P, Xu J, Williams K, Easley M, et al
    Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Neuro Oncol. 2021 Jul 14. pii: 6321319. doi: 10.1093.
    PubMed     Abstract available


  484. LUDWIG N, Rao A, Sandlesh P, Yerneni SS, et al
    Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
    Neuro Oncol. 2021 Jul 13. pii: 6320007. doi: 10.1093.
    PubMed     Abstract available


  485. RAMASWAMY V, Bartels U
    Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
    Neuro Oncol. 2021 Jul 12. pii: 6319139. doi: 10.1093.
    PubMed    


  486. BALANA C, Sun C, Vaz MA, Esteve A, et al
    Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318238. doi: 10.1093.
    PubMed    


  487. TERABE M, Wu J
    Rethinking Immunotherapy in Meningiomas.
    Neuro Oncol. 2021 Jul 9. pii: 6318447. doi: 10.1093.
    PubMed    


  488. ZHAO B, Ma W
    Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318242. doi: 10.1093.
    PubMed    


  489. BAGLEY SJ, Kline CN
    Understanding the global impact of primary brain tumors: the untapped potential of population-based cancer registries.
    Neuro Oncol. 2021 Jul 9. pii: 6318451. doi: 10.1093.
    PubMed    


  490. LUKAS RV
    Essential Oils for Blood-Brain Barrier Disruption: Preclinical Studies of NEO100 in Breast Cancer Brain Metastases.
    Neuro Oncol. 2021 Jul 9. pii: 6318449. doi: 10.1093.
    PubMed    


  491. ALHALABI OT, Fletcher MNC, Hielscher T, Kessler T, et al
    A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
    Neuro Oncol. 2021 Jul 7. pii: 6316731. doi: 10.1093.
    PubMed     Abstract available


  492. TONOGAI EJ, Huang S, Botham RC, Berry MR, et al
    Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
    Neuro Oncol. 2021 Jul 3. pii: 6314291. doi: 10.1093.
    PubMed     Abstract available


  493. TEHRANIAN C, Fankhauser L, Harter PN, Ratcliffe CDH, et al
    The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
    Neuro Oncol. 2021 Jul 3. pii: 6314211. doi: 10.1093.
    PubMed     Abstract available


  494. PETRIDIS PD, Horenstein C, Pereira B, Wu P, et al
    BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas.
    Neuro Oncol. 2021 Jul 2. pii: 6313213. doi: 10.1093.
    PubMed     Abstract available


  495. YAMAZAKI S, Ohka F, Hirano M, Shiraki Y, et al
    Newly Established Patient-derived Organoid Model of Intracranial Meningioma.
    Neuro Oncol. 2021 Jul 2. pii: 6313216. doi: 10.1093.
    PubMed     Abstract available


  496. D'ALESSANDRIS QG, Della Pepa GM, Noya C, Olivi A, et al
    Mesenchymal stem cells: are they the good or the bad?
    Neuro Oncol. 2021;23:1203-1204.
    PubMed    


  497. DANKNER M, Maritan SM
    The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes.
    Neuro Oncol. 2021;23:1207.
    PubMed    


  498. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic factors in leptomeningeal metastases.
    Neuro Oncol. 2021;23:1208-1209.
    PubMed    


  499. BARAJAS RF, Politi LS, Anzalone N, Schoder H, et al
    Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
    Neuro Oncol. 2021;23:1056-1071.
    PubMed     Abstract available


  500. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
    Neuro Oncol. 2021;23:1100-1112.
    PubMed     Abstract available


  501. FORDE C, King AT, Rutherford SA, Hammerbeck-Ward C, et al
    Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
    Neuro Oncol. 2021;23:1113-1124.
    PubMed     Abstract available


    June 2021
  502. GOLDBRUNNER R, Stavrinou P, Jenkinson MD, Sahm F, et al
    EANO guideline on the diagnosis and management of meningiomas.
    Neuro Oncol. 2021 Jun 28. pii: 6310843. doi: 10.1093.
    PubMed     Abstract available


  503. WALBERT T, Harrison RA, Schiff D, Avila EK, et al
    SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310125. doi: 10.1093.
    PubMed     Abstract available


  504. PENG J, Kim DD, Patel JB, Zeng X, et al
    Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310123. doi: 10.1093.
    PubMed     Abstract available


  505. WIRSCHING HG, Steiner L, Becker D, Regli L, et al
    Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression.
    Neuro Oncol. 2021 Jun 19. pii: 6305986. doi: 10.1093.
    PubMed    


  506. JOHNSON KC, Verhaak RGW
    Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring.
    Neuro Oncol. 2021 Jun 17. pii: 6302547. doi: 10.1093.
    PubMed    


  507. HAU P
    Dissecting adult SHH-activated medulloblastoma - molecularly defined tumor subsets reveal new prognostic biomarkers.
    Neuro Oncol. 2021 Jun 17. pii: 6302543. doi: 10.1093.
    PubMed    


  508. SHAH AH, Gilbert M, Ivan ME, Komotar RJ, et al
    The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications.
    Neuro Oncol. 2021 Jun 12. pii: 6297568. doi: 10.1093.
    PubMed     Abstract available


  509. ERKER C, Lane A, Chaney B, Leary S, et al
    Characteristics of Patients >/= 10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry.
    Neuro Oncol. 2021 Jun 11. pii: 6296498. doi: 10.1093.
    PubMed     Abstract available


  510. SHEEHAN J, Pikis S, Islim A, Chen CJ, et al
    An International Multicenter Matched Cohort Analysis of Incidental Meningioma Progression During Active Surveillance or After Stereotactic Radiosurgery: The IMPASSE Study.
    Neuro Oncol. 2021 Jun 9. pii: 6295369. doi: 10.1093.
    PubMed     Abstract available


  511. KOTECHA R, Aboian M, Nabavizadeh SA, Parent EE, et al
    Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291736. doi: 10.1093.
    PubMed    


  512. GALLDIKS N, Niyazi M, Tonn JC, Langen KJ, et al
    Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291737. doi: 10.1093.
    PubMed    


  513. RIEMONDY KA, Venkataraman S, Willard N, Nellan A, et al
    Neoplastic and immune single cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.
    Neuro Oncol. 2021 Jun 2. pii: 6291352. doi: 10.1093.
    PubMed     Abstract available


  514. RITZMANN TA, Kilday JP, Grundy RG
    Pediatric ependymomas: destined to recur?
    Neuro Oncol. 2021;23:874-876.
    PubMed    


  515. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States.
    Neuro Oncol. 2021;23:979-989.
    PubMed     Abstract available


  516. ADOLPH JE, Fleischhack G, Mikasch R, Zeller J, et al
    Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
    Neuro Oncol. 2021;23:1012-1023.
    PubMed     Abstract available


    May 2021
  517. PHILLIPS LM, Li S, Gumin J, Daou M, et al
    An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Neuro Oncol. 2021 May 31. pii: 6290257. doi: 10.1093.
    PubMed     Abstract available


  518. MARIN BM, Porath KA, Jain S, Kim M, et al
    Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
    Neuro Oncol. 2021 May 29. pii: 6288409. doi: 10.1093.
    PubMed     Abstract available


  519. SCOCCIANTI S, Olmetto E, Pinzi V, Osti MF, et al
    Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
    Neuro Oncol. 2021 May 29. pii: 6288399. doi: 10.1093.
    PubMed     Abstract available


  520. VERBURG N, Barthel FP, Anderson KJ, Johnson KC, et al
    Spatial concordance of DNA methylation classification in diffuse glioma.
    Neuro Oncol. 2021 May 28. pii: 6287958. doi: 10.1093.
    PubMed     Abstract available


  521. SIMOVIC M, Bolkestein M, Moustafa M, Wong JKL, et al
    Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
    Neuro Oncol. 2021 May 28. pii: 6287957. doi: 10.1093.
    PubMed     Abstract available


  522. DE ANDRADE COSTA A, Chatterjee J, Cobb O, Sanapala S, et al
    RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth.
    Neuro Oncol. 2021 May 27. pii: 6286081. doi: 10.1093.
    PubMed     Abstract available


  523. LI Y, Wang X, Qi S, Gao L, et al
    Spliceosome-regulated RSRP1-dependent NF-kappaB activation promotes the glioblastoma mesenchymal phenotype.
    Neuro Oncol. 2021 May 27. pii: 6286882. doi: 10.1093.
    PubMed     Abstract available


  524. LAPERRIERE NJ
    Protons for the Management of Adult Patients with Glioblastoma.
    Neuro Oncol. 2021 May 24. pii: 6283746. doi: 10.1093.
    PubMed    


  525. MENDOZA TR
    Especially for neuro-oncologists - minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 May 24. pii: 6283743. doi: 10.1093.
    PubMed    


  526. CHONGSATHIDKIET P, Fecci PE
    Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases.
    Neuro Oncol. 2021 May 24. pii: 6283744. doi: 10.1093.
    PubMed    


  527. BI WL, Nayak L, Meredith DM, Driver J, et al
    Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.
    Neuro Oncol. 2021 May 20. pii: 6279078. doi: 10.1093.
    PubMed     Abstract available


  528. GUSYATINER O, Bady P, Pham MDT, Lei Y, et al
    BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
    Neuro Oncol. 2021 May 14. pii: 6275457. doi: 10.1093.
    PubMed     Abstract available


  529. SIM HW, McDonald KL, Lwin Z, Barnes EH, et al
    A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
    Neuro Oncol. 2021 May 13. pii: 6275307. doi: 10.1093.
    PubMed     Abstract available


  530. DAHL NA, Vibhakar R
    Converging evidence for inhibition of transcriptional control in high-grade gliomas.
    Neuro Oncol. 2021 May 13. pii: 6275360. doi: 10.1093.
    PubMed    


  531. TAKAI S, Wanibuchi M, Kawabata S, Takeuchi K, et al
    Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up.
    Neuro Oncol. 2021 May 13. pii: 6275296. doi: 10.1093.
    PubMed     Abstract available


  532. BAO Z, Hua L, Ye Y, Wang D, et al
    MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.
    Neuro Oncol. 2021 May 13. pii: 6275374. doi: 10.1093.
    PubMed     Abstract available


  533. WANG Z, Gao L, Wang Y, Chang M, et al
    Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma.
    Neuro Oncol. 2021 May 13. pii: 6275034. doi: 10.1093.
    PubMed    


  534. NASSIRI F, Wang JZ, Singh O, Karimi S, et al
    Loss of H3K27me3 in meningiomas.
    Neuro Oncol. 2021 May 10. pii: 6273127. doi: 10.1093.
    PubMed     Abstract available


  535. FELKER J, Agnihotri S
    Not all mouse blood-brain barriers are created equal.
    Neuro Oncol. 2021;23:705-706.
    PubMed    


  536. SO J, Mamatjan Y, Zadeh G, Aldape K, et al
    Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.
    Neuro Oncol. 2021;23:795-802.
    PubMed     Abstract available


  537. MASSIMINO M, Barretta F, Modena P, Witt H, et al
    Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.
    Neuro Oncol. 2021;23:848-857.
    PubMed     Abstract available


  538. CLAUS EB, Cannataro VL, Gaffney SG, Townsend JP, et al
    Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2021 May 4. pii: 6263733. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  539. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review.
    Neuro Oncol. 2021 Apr 30. pii: 6263562. doi: 10.1093.
    PubMed     Abstract available


  540. YEUNG J, Yaghoobi V, Miyagishima D, Vesely MD, et al
    Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.
    Neuro Oncol. 2021 Apr 29. pii: 6259024. doi: 10.1093.
    PubMed     Abstract available


  541. TESILEANU CMS, van den Bent MJ, Sanson M, Wick W, et al
    Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
    Neuro Oncol. 2021 Apr 29. pii: 6259004. doi: 10.1093.
    PubMed     Abstract available


  542. LAMBA N, Wen PY, Aizer AA
    Epidemiology of Brain Metastases and Leptomeningeal Disease.
    Neuro Oncol. 2021 Apr 28. pii: 6256866. doi: 10.1093.
    PubMed     Abstract available


  543. STROTHER D, Lafay-Cousin L
    Adjuvant therapy for high risk medulloblastoma: More is better?
    Neuro Oncol. 2021 Apr 27. pii: 6254485. doi: 10.1093.
    PubMed    


  544. MARINELLI JP, Carlson ML
    Potential for selection bias surrounding reporting of benign brain tumors in the United States.
    Neuro Oncol. 2021 Apr 26. pii: 6253739. doi: 10.1093.
    PubMed    


  545. TAWBI HA, Forsyth PA, Hodi FS, Lao CD, et al
    Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
    Neuro Oncol. 2021 Apr 21. pii: 6242717. doi: 10.1093.
    PubMed     Abstract available


  546. NICLOU SP, Golebiewska A
    Turning strength into weakness: protein degradation and autophagy as therapeutic targets in Glioblastoma?
    Neuro Oncol. 2021 Apr 17. pii: 6231737. doi: 10.1093.
    PubMed    


  547. SCHNEIDER M, Vollmer L, Potthoff AL, Ravi VM, et al
    Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
    Neuro Oncol. 2021 Apr 17. pii: 6231712. doi: 10.1093.
    PubMed     Abstract available


  548. VISWANATH P, Batsios G, Ayyappan V, Taglang C, et al
    Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
    Neuro Oncol. 2021 Apr 17. pii: 6231711. doi: 10.1093.
    PubMed     Abstract available


  549. VOLMAR MNM, Cheng J, Alenezi H, Richter S, et al
    Cannabidiol converts NFkappaB into a tumor suppressor in glioblastoma with defined antioxidative properties.
    Neuro Oncol. 2021 Apr 17. pii: 6231710. doi: 10.1093.
    PubMed     Abstract available


  550. KATSUSHIMA K, Lee B, Kunhiraman H, Zhong C, et al
    The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas.
    Neuro Oncol. 2021;23:572-585.
    PubMed     Abstract available


  551. THOMAS C, Soschinski P, Zwaig M, Oikonomopoulos S, et al
    The genetic landscape of choroid plexus tumors in children and adults.
    Neuro Oncol. 2021;23:650-660.
    PubMed     Abstract available


  552. WANIS HA, Moller H, Ashkan K, Davies EA, et al
    The incidence of major subtypes of primary brain tumours in adults in England 1995-2017.
    Neuro Oncol. 2021 Apr 9. pii: 6218679. doi: 10.1093.
    PubMed     Abstract available


  553. HORBINSKI C, McCortney K, Stupp R
    MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 8. pii: 6217333. doi: 10.1093.
    PubMed    


  554. MUKHERJEE S, Schiltz G, Clutter M, Mishra R, et al
    Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS.
    Neuro Oncol. 2021 Apr 7. pii: 6214067. doi: 10.1093.
    PubMed    


  555. MUKHERJEE S, Olson C, Dundar B, Sharma N, et al
    Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5-CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA STEM CELLS.
    Neuro Oncol. 2021 Apr 7. pii: 6214066. doi: 10.1093.
    PubMed    


  556. FRAPPAZ D, Barritault M, Montane L, Laigle-Donadey F, et al
    MEVITEM - A Phase I/II of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Neuro Oncol. 2021 Apr 7. pii: 6213882. doi: 10.1093.
    PubMed     Abstract available


  557. YU Y, Villanueva-Meyer J, Grimmer MR, Hilz S, et al
    Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 5. pii: 6211336. doi: 10.1093.
    PubMed     Abstract available


  558. SANTAGATA S, Ligon KL
    Prognostication for meningiomas: H3K27me3 to the rescue?
    Neuro Oncol. 2021 Apr 3. pii: 6209863. doi: 10.1093.
    PubMed    


  559. TSANG DS, Schulte F
    Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship.
    Neuro Oncol. 2021 Apr 3. pii: 6209877. doi: 10.1093.
    PubMed    


  560. LEE EQ, Selig W, Meehan C, Bacha J, et al
    Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.
    Neuro Oncol. 2021 Apr 2. pii: 6209406. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  561. PERKINS S, Acharya S
    Radiation therapy to the developing brain: advanced technology is ready for robust optimization parameters.
    Neuro Oncol. 2021;23:350-351.
    PubMed    


  562. LASSMAN AB, Cloughesy TF
    Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
    Neuro Oncol. 2021;23:347-349.
    PubMed    


  563. KUMTHEKAR P, Dunbar EM, Peters KB, Brastianos PK, et al
    A broad perspective on evaluating bias in the neuro-oncology workplace.
    Neuro Oncol. 2021;23:498-499.
    PubMed    


  564. GILBERT MR, Yuan Y, Wu J, Mendoza T, et al
    A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
    Neuro Oncol. 2021;23:468-477.
    PubMed     Abstract available


  565. JAECKLE KA, Ballman KV, van den Bent M, Giannini C, et al
    CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
    Neuro Oncol. 2021;23:457-467.
    PubMed     Abstract available


  566. BOURDEAUT F
    Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?
    Neuro Oncol. 2021 Mar 23. pii: 6182498. doi: 10.1093.
    PubMed    


  567. LU SL, Xiao FR, Cheng JC, Yang WC, et al
    Randomized Multi-Reader Evaluation of Automated Detection and Segmentation of Brain Tumors in Stereotactic Radiosurgery with Deep Neural Networks.
    Neuro Oncol. 2021 Mar 23. pii: 6180141. doi: 10.1093.
    PubMed     Abstract available


  568. LATHIA JD
    Fountain of chaos: cerebrospinal fluid enhancement of cancer stem cells in glioblastoma.
    Neuro Oncol. 2021 Mar 22. pii: 6179836. doi: 10.1093.
    PubMed    


  569. NOBRE L, Ramaswamy V
    Medulloblastoma (cross)talk through extracellular vesicles.
    Neuro Oncol. 2021 Mar 22. pii: 6179837. doi: 10.1093.
    PubMed    


  570. OSTROM QT, Edelson J, Byun J, Han Y, et al
    Partitioned glioma heritability shows subtype-specific enrichment in immune cells.
    Neuro Oncol. 2021 Mar 20. pii: 6179266. doi: 10.1093.
    PubMed     Abstract available


  571. GIRARDI F, Rous B, Stiller CA, Gatta G, et al
    The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3).
    Neuro Oncol. 2021 Mar 19. pii: 6178525. doi: 10.1093.
    PubMed     Abstract available


  572. VERKOUTEREN BJA, Cosgun B, Vermeulen RJ, Reinders MGHC, et al
    Prevalence of medulloblastoma in basal cell nevus syndrome patients with a PTCH1 mutation.
    Neuro Oncol. 2021 Mar 17. pii: 6231902. doi: 10.1093.
    PubMed    


  573. TSIEN C
    Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?
    Neuro Oncol. 2021 Mar 12. pii: 6168946. doi: 10.1093.
    PubMed    


  574. WINKLER F
    In glioma, all endothelial cells are not created the same.
    Neuro Oncol. 2021 Mar 11. pii: 6168415. doi: 10.1093.
    PubMed    


  575. SAIT SF, Karajannis MA
    Pediatric spinal cord gliomas - low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?
    Neuro Oncol. 2021 Mar 11. pii: 6168346. doi: 10.1093.
    PubMed    


  576. TRIFILETTI DM, Brown PD
    Cognitive outcomes in patients with low-grade glioma.
    Neuro Oncol. 2021 Mar 11. pii: 6168225. doi: 10.1093.
    PubMed    


  577. FONSECA A, Bouffet E
    Brainstem Gliomas... The Devil is in the Details.
    Neuro Oncol. 2021 Mar 11. pii: 6168340. doi: 10.1093.
    PubMed    


  578. BAUMERT BG, Pesce GA
    Elderly patients with brain metastases: new support for the balancing act in treatment decision making.
    Neuro Oncol. 2021 Mar 11. pii: 6168221. doi: 10.1093.
    PubMed    


  579. MENG Y, Pople CB, Suppiah S, Llinas M, et al
    MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
    Neuro Oncol. 2021 Mar 10. pii: 6167330. doi: 10.1093.
    PubMed     Abstract available


  580. LIM-FAT MJ, Maralani PJ
    Is there an optimal MRI surveillance schedule for patients with high grade glioma after standard of care therapy?
    Neuro Oncol. 2021 Mar 1. pii: 6155531. doi: 10.1093.
    PubMed    


  581. SPERDUTO PW, Lou E
    The Past, Current and Future Management of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.
    Neuro Oncol. 2021 Mar 1. pii: 6155599. doi: 10.1093.
    PubMed    


    February 2021
  582. GIANNINI C, Giangaspero F
    TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH-wildtype glioblastoma?
    Neuro Oncol. 2021 Feb 28. pii: 6154503. doi: 10.1093.
    PubMed    


  583. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Feb 28. pii: 6154448. doi: 10.1093.
    PubMed     Abstract available


  584. BROWN PD, Chung C, Liu DD, McAvoy S, et al
    A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2021 Feb 27. pii: 6154000. doi: 10.1093.
    PubMed     Abstract available


  585. JESSURUN CAC, Hulsbergen AFC, de Wit AE, Tewarie IA, et al
    The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.
    Neuro Oncol. 2021 Feb 25. pii: 6150018. doi: 10.1093.
    PubMed     Abstract available


  586. FANGUSARO J, Onar-Thomas A, Poussaint TY, Wu S, et al
    A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2021 Feb 25. pii: 6149924. doi: 10.1093.
    PubMed     Abstract available


  587. TSCHERNICHOVSKY R, Katz LH, Derazne E, Berliner MB, et al
    Height in Adolescence as a Risk Factor for Glioma Subtypes: a Nationwide Retrospective Cohort Study of 2.2 Million Subjects.
    Neuro Oncol. 2021 Feb 25. pii: 6149925. doi: 10.1093.
    PubMed     Abstract available


  588. JAIN R, Chi AS
    Radiogenomics identifying important biological pathways in gliomas.
    Neuro Oncol. 2021;23:177-178.
    PubMed    


  589. ELLINGSON BM, Brown MS, Boxerman JL, Gerstner ER, et al
    Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
    Neuro Oncol. 2021;23:189-198.
    PubMed     Abstract available


  590. KANAMORI M, Takami H, Yamaguchi S, Sasayama T, et al
    So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?
    Neuro Oncol. 2021;23:295-303.
    PubMed     Abstract available


  591. CANNON-ALBRIGHT LA, Farnham JM, Stevens J, Teerlink CC, et al
    Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene.
    Neuro Oncol. 2021;23:277-283.
    PubMed     Abstract available


  592. MATHEN P, Smart DK
    Reimagining External Beam Radiotherapy for Glioblastoma: "Old Beam, New Trick".
    Neuro Oncol. 2021 Feb 22. pii: 6146614. doi: 10.1093.
    PubMed    


  593. KIM MM, Aryal MP, Sun Y, Parmar HA, et al
    Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2021 Feb 18. pii: 6144576. doi: 10.1093.
    PubMed     Abstract available


  594. DIRVEN L, Musoro JZ, Coens C, Reijneveld JC, et al
    Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 Feb 18. pii: 6142946. doi: 10.1093.
    PubMed     Abstract available


  595. KORSHUNOV A, Okonechnikov K, Stichel D, Ryzhova M, et al
    Integrated molecular analysis of adult Sonic Hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
    Neuro Oncol. 2021 Feb 16. pii: 6137557. doi: 10.1093.
    PubMed     Abstract available


  596. HUANG T, Cheng SY
    Targeting phospholipid metabolism for glioblastoma therapy.
    Neuro Oncol. 2021 Feb 9. pii: 6131652. doi: 10.1093.
    PubMed    


  597. SCHAFFENRATH J, Wyss T, He L, Rushing EJ, et al
    Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.
    Neuro Oncol. 2021 Feb 9. pii: 6131739. doi: 10.1093.
    PubMed     Abstract available


  598. SABEDOT T, Malta T, Snyder J, Nelson K, et al
    A serum-based DNA methylation assay provides accurate detection of glioma.
    Neuro Oncol. 2021 Feb 9. pii: 6131768. doi: 10.1093.
    PubMed     Abstract available


  599. GRAILLON T, Ferrer L, Siffre J, Sanson M, et al
    Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
    Neuro Oncol. 2021 Feb 8. pii: 6131353. doi: 10.1093.
    PubMed     Abstract available


  600. GUO X, Wang S, Wang Y, Ma W, et al
    Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131355. doi: 10.1093.
    PubMed    


  601. YAMAMOTO M, Sanomachi T, Suzuki S, Uchida H, et al
    Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
    Neuro Oncol. 2021 Feb 8. pii: 6131352. doi: 10.1093.
    PubMed     Abstract available


  602. OTANI Y, Sur H, Rachaiah G, Namagiri S, et al
    Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131351. doi: 10.1093.
    PubMed     Abstract available


  603. TORRES VA, Ashford JM, Wright E, Xu J, et al
    The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial.
    Neuro Oncol. 2021 Feb 5. pii: 6128895. doi: 10.1093.
    PubMed     Abstract available


  604. LIAO Y, Luo Z, Deng Y, Zhang F, et al
    OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Neuro Oncol. 2021 Feb 4. pii: 6128721. doi: 10.1093.
    PubMed     Abstract available


  605. GALLDIKS N, Niyazi M, Grosu AL, Kocher M, et al
    Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
    Neuro Oncol. 2021 Feb 4. pii: 6128548. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  606. WEFEL JS, Armstrong TS, Pugh SL, Gilbert MR, et al
    Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825).
    Neuro Oncol. 2021 Jan 30. pii: 6124000. doi: 10.1093.
    PubMed     Abstract available


  607. YANG TJ, Wijetunga NA, Yamada J, Wolden S, et al
    Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.
    Neuro Oncol. 2021;23:134-143.
    PubMed     Abstract available


  608. NARITA Y, Nagane M, Mishima K, Terui Y, et al
    Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Neuro Oncol. 2021;23:122-133.
    PubMed     Abstract available


  609. MAIRE CL, Fuh MM, Kaulich K, Fita KD, et al
    Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification.
    Neuro Oncol. 2021 Jan 28. pii: 6122789. doi: 10.1093.
    PubMed     Abstract available


  610. GERRITSEN JKW, Vincent AJPE, De Vleeschouwer S
    Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome.
    Neuro Oncol. 2021 Jan 20. pii: 6104892. doi: 10.1093.
    PubMed    


  611. VARGAS LOPEZ AJ
    Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
    Neuro Oncol. 2021 Jan 20. pii: 6104916. doi: 10.1093.
    PubMed    


  612. DIAMANDIS P
    De-coding group 3 medulloblastoma biology with non-coding RNA.
    Neuro Oncol. 2021 Jan 20. pii: 6104902. doi: 10.1093.
    PubMed    


  613. KATAGI H, Takata N, Aoi Y, Zhang Y, et al
    Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Neuro Oncol. 2021 Jan 20. pii: 6104638. doi: 10.1093.
    PubMed     Abstract available


  614. WEN PY, Weller M, Chiocca EA, Lim M, et al
    Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez.
    Neuro Oncol. 2021 Jan 20. pii: 6104896. doi: 10.1093.
    PubMed    


  615. FULTS DW
    Stemming the growth of pediatric gliomas through histone modification.
    Neuro Oncol. 2021 Jan 20. pii: 6104497. doi: 10.1093.
    PubMed    


  616. DMYTRIW AA, Huang RY
    In search of predictive and response markers in antiangiogenic therapy of glioblastoma.
    Neuro Oncol. 2021 Jan 20. pii: 6104491. doi: 10.1093.
    PubMed    


  617. DANKNER M, Caron M, Al-Saadi T, Yu W, et al
    Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases.
    Neuro Oncol. 2021 Jan 12. pii: 6089125. doi: 10.1093.
    PubMed     Abstract available


  618. WU S, Li X, Gao F, de Groot JF, et al
    PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Neuro Oncol. 2021 Jan 12. pii: 6089123. doi: 10.1093.
    PubMed     Abstract available


  619. BENITEZ JA, Finlay D, Castanza A, Parisian AD, et al
    Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.
    Neuro Oncol. 2021 Jan 11. pii: 6081306. doi: 10.1093.
    PubMed     Abstract available


  620. GUTMAN DC, Young RJ
    IDH glioma radiogenomics in the era of deep learning.
    Neuro Oncol. 2021 Jan 8. pii: 6068851. doi: 10.1093.
    PubMed    


  621. SNUDERL M
    Molecular classification and deconvolution of the immune microenvironment in glioblastoma.
    Neuro Oncol. 2021 Jan 4. pii: 6062458. doi: 10.1093.
    PubMed    


  622. SHOFUDA T, Kanemura Y
    HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
    Neuro Oncol. 2021 Jan 4. pii: 6062389. doi: 10.1093.
    PubMed    


    December 2020
  623. SHAHZAD U, Taccone MS, Kumar SA, Okura H, et al
    Modeling human brain tumours in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.
    Neuro Oncol. 2020 Dec 30. pii: 6055605. doi: 10.1093.
    PubMed     Abstract available


  624. DUFOUR C, Foulon S, Geoffray A, Masliah-Planchon J, et al
    Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.
    Neuro Oncol. 2020 Dec 30. pii: 6055191. doi: 10.1093.
    PubMed     Abstract available


  625. CHUNTOVA P, Chow F, Watchmaker P, Galvez M, et al
    Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.
    Neuro Oncol. 2020 Dec 24. pii: 6047273. doi: 10.1093.
    PubMed     Abstract available


  626. BEHLING F, Fodi C, Gepfner-Tuma I, Kaltenbach K, et al
    H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort.
    Neuro Oncol. 2020 Dec 24. pii: 6046432. doi: 10.1093.
    PubMed     Abstract available


  627. KUKSIS M, Gao Y, Tran W, Hoey C, et al
    The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Neuro Oncol. 2020 Dec 23. pii: 6046194. doi: 10.1093.
    PubMed     Abstract available


  628. CARLSON JC, Cantu-Gutierrez M, Lozzi B, Huang-Hobbs E, et al
    Identification of diverse tumor endothelial cell populations in malignant glioma.
    Neuro Oncol. 2020 Dec 23. pii: 6046199. doi: 10.1093.
    PubMed     Abstract available


  629. PATIL N, Kelly ME, Yeboa DN, Buerki RA, et al
    Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017.
    Neuro Oncol. 2020 Dec 21. pii: 6042829. doi: 10.1093.
    PubMed     Abstract available


  630. PERWEIN T, Benesch M, Kandels D, Pietsch T, et al
    High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group.
    Neuro Oncol. 2020 Dec 21. pii: 6042812. doi: 10.1093.
    PubMed     Abstract available


  631. BERNHARDT D, Combs SE
    Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".
    Neuro Oncol. 2020;22:1893.
    PubMed    


  632. YANG Z, Zhang Y, Li R, Yisikandaer A, et al
    Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
    Neuro Oncol. 2020 Dec 17. pii: 6040795. doi: 10.1093.
    PubMed     Abstract available


  633. LIU Y, Li Z, Zhang M, Zhou H, et al
    Rolling-translated EGFR Variants Sustain EGFR Signaling and Promote Glioblastoma Tumorigenicity.
    Neuro Oncol. 2020 Dec 16. pii: 6039055. doi: 10.1093.
    PubMed     Abstract available


  634. HAYDAR D, Houke H, Chiang J, Yi Z, et al
    Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Neuro Oncol. 2020 Dec 15. pii: 6035165. doi: 10.1093.
    PubMed     Abstract available


  635. XIE R, Kessler T, Grosch J, Hai L, et al
    Tumor cell network integration in glioma represents a stemness feature.
    Neuro Oncol. 2020 Dec 15. pii: 6035154. doi: 10.1093.
    PubMed     Abstract available


  636. PUDUVALLI VK
    Demystifying Demethylator Sensitivity in Gliomas: Role for TERT and DNMT1.
    Neuro Oncol. 2020 Dec 2. pii: 6017324. doi: 10.1093.
    PubMed    


  637. HUANG J, Mehta M
    Can proton therapy reduce radiation-related lymphopenia in glioblastoma?
    Neuro Oncol. 2020 Dec 2. pii: 6017294. doi: 10.1093.
    PubMed    


  638. GENOVESI LA, Puttick S, Millar A, Kojic M, et al
    Patient derived orthotopic xenograft models of Medulloblastoma lack a functional blood brain barrier.
    Neuro Oncol. 2020 Dec 1. pii: 6015057. doi: 10.1093.
    PubMed     Abstract available


  639. YUAN M, White D, Resar L, Bar E, et al
    Conditional reprograming culture conditions facilitate growth of lower grade glioma models.
    Neuro Oncol. 2020 Dec 1. pii: 6015051. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  640. KHASRAW M, Walsh KM, Heimberger AB, Ashley DM, et al
    What is the Burden of Proof for Tumor Mutational Burden in gliomas?
    Neuro Oncol. 2020 Nov 30. pii: 6012765. doi: 10.1093.
    PubMed     Abstract available


  641. LARA-VELAZQUEZ M, Zarco N, Carrano A, Phillipps J, et al
    Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.
    Neuro Oncol. 2020 Nov 29. pii: 6010432. doi: 10.1093.
    PubMed     Abstract available


  642. ZHENG ZQ, Chen JT, Zheng MC, Yang LJ, et al
    Nestin +/CD31 + Cells in the Hypoxic Perivascular Niche Regulate Glioblastoma Chemoresistance by Upregulating JAG1 and DLL4.
    Neuro Oncol. 2020 Nov 29. pii: 6010441. doi: 10.1093.
    PubMed     Abstract available


  643. NIU X, Yang Y, Zhou X, Zhang H, et al
    A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.
    Neuro Oncol. 2020 Nov 27. pii: 6007003. doi: 10.1093.
    PubMed    


  644. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Response to Letter to Editor.
    Neuro Oncol. 2020;22:1706-1707.
    PubMed    


  645. LE RHUN E, Weller M, Le Deley MC
    DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?
    Neuro Oncol. 2020;22:1710-1711.
    PubMed    


  646. VOGELBAUM MA, Krivosheya D, Borghei-Razavi H, Sanai N, et al
    Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
    Neuro Oncol. 2020;22:1568-1579.
    PubMed     Abstract available


  647. OERMANN EK, Germano IM
    In the pursuit of glioma diagnosis - the challenges and opportunities of deep neural network augmented analyses.
    Neuro Oncol. 2020 Nov 12. pii: 5979500. doi: 10.1093.
    PubMed    


  648. ALBERT TK, Interlandi M, Sill M, Graf M, et al
    An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.
    Neuro Oncol. 2020 Nov 11. pii: 5974128. doi: 10.1093.
    PubMed     Abstract available


  649. MITCHELL K, Troike K, Silver DJ, Lathia JD, et al
    The evolution of the cancer stem cell state in glioblastoma - emerging insights into the next-generation of functional interactions.
    Neuro Oncol. 2020 Nov 11. pii: 5973946. doi: 10.1093.
    PubMed     Abstract available


  650. BERZERO G, Di Stefano AL, Ronchi S, Bielle F, et al
    IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Neuro Oncol. 2020 Nov 11. pii: 5973947. doi: 10.1093.
    PubMed     Abstract available


  651. GRAMATZKI D, Felsberg J, Roth P, Kaulich K, et al
    The molecular evolution of glioblastoma treated by gross total resection alone.
    Neuro Oncol. 2020 Nov 11. pii: 5973944. doi: 10.1093.
    PubMed    


  652. SAHEBJAM S, Forsyth PA, Tran ND, Arrington JA, et al
    Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study.
    Neuro Oncol. 2020 Nov 11. pii: 5973945. doi: 10.1093.
    PubMed     Abstract available


  653. YI K, Zhan Q, Wang Q, Tan Y, et al
    PTRF/Cavin1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
    Neuro Oncol. 2020 Nov 3. pii: 5952479. doi: 10.1093.
    PubMed     Abstract available


  654. VITANZA NA, Biery MC, Myers C, Ferguson E, et al
    Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models.
    Neuro Oncol. 2020 Nov 1. pii: 5948533. doi: 10.1093.
    PubMed     Abstract available


  655. MANJUNATH M, Yan J, Youn Y, Drucker KL, et al
    Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.
    Neuro Oncol. 2020 Nov 1. pii: 5948532. doi: 10.1093.
    PubMed     Abstract available


  656. DEJAEGHER J, Solie L, Hunin Z, Sciot R, et al
    DNA Methylation based glioblastoma subclassification is related to tumoral T cell infiltration and patient survival.
    Neuro Oncol. 2020 Nov 1. pii: 5948531. doi: 10.1093.
    PubMed     Abstract available


  657. KLEIN M, Drijver AJ, van den Bent MJ, Bromberg JC, et al
    Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033.
    Neuro Oncol. 2020 Nov 1. pii: 5948535. doi: 10.1093.
    PubMed     Abstract available


  658. SIEVERS P, Sill M, Schrimpf D, Stichel D, et al
    A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
    Neuro Oncol. 2020 Nov 1. pii: 5948536. doi: 10.1093.
    PubMed     Abstract available


  659. JI SY, Lee J, Lee JH, Lee ST, et al
    Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.
    Neuro Oncol. 2020 Nov 1. pii: 5948534. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  660. OSTROM QT, Patil N, Cioffi G, Waite K, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
    Neuro Oncol. 2020;22.
    PubMed     Abstract available


  661. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2020 Oct 28. pii: 5942594. doi: 10.1093.
    PubMed    


  662. CICONE F, Carideo L, Scaringi C, Romano A, et al
    Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.
    Neuro Oncol. 2020 Oct 23. pii: 5936979. doi: 10.1093.
    PubMed     Abstract available


  663. MYNAREK M, Rutkowski S
    Young children with medulloblastoma: Important open questions and the high-risk dilemma.
    Neuro Oncol. 2020 Oct 23. pii: 5936023. doi: 10.1093.
    PubMed    


  664. GONDI V, Mehta MP
    Radiotherapy Innovations to Optimize Brain Metastases Control.
    Neuro Oncol. 2020 Oct 22. pii: 5934824. doi: 10.1093.
    PubMed    


  665. BROSSIER NM, Thondapu S, Cobb OM, Dahiya S, et al
    Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma.
    Neuro Oncol. 2020 Oct 20. pii: 5932401. doi: 10.1093.
    PubMed     Abstract available


  666. CHO SJ, Sunwoo L, Baik SH, Bae YJ, et al
    Brain Metastasis Detection using Machine Learning: A Systematic Review and Meta-analysis.
    Neuro Oncol. 2020 Oct 19. pii: 5930826. doi: 10.1093.
    PubMed     Abstract available


  667. GROSSMAN SA
    The Duration of Adjuvant Temozolomide in Patients with Glioblastoma and the Law of Diminishing Returns.
    Neuro Oncol. 2020 Oct 19. pii: 5930402. doi: 10.1093.
    PubMed    


  668. SKINNER KR, Nabors LB, Miller CR
    Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
    Neuro Oncol. 2020 Oct 19. pii: 5930390. doi: 10.1093.
    PubMed    


  669. ZHUANG H, Wang Y, Cheng C, Shi S, et al
    The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy.
    Neuro Oncol. 2020 Oct 19. pii: 5930379. doi: 10.1093.
    PubMed    


  670. YOUNGBLOOD MW, Miyagishima DF, Jin L, Gupte T, et al
    Associations of Meningioma Molecular Subgroup and Tumor Recurrence.
    Neuro Oncol. 2020 Oct 17. pii: 5928913. doi: 10.1093.
    PubMed     Abstract available


  671. LAMBA N, Kearney RB, Catalano PJ, Hassett MJ, et al
    Population-based estimates of survival among elderly patients with brain metastases.
    Neuro Oncol. 2020 Oct 17. pii: 5929216. doi: 10.1093.
    PubMed     Abstract available


  672. BEIG N, Singh S, Bera K, Prasanna P, et al
    Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in Glioblastoma.
    Neuro Oncol. 2020 Oct 17. pii: 5929182. doi: 10.1093.
    PubMed     Abstract available


  673. BINDRA RS
    Penetrating the Brain Tumor Space with DNA Damage Response Inhibitors.
    Neuro Oncol. 2020 Oct 16. pii: 5924496. doi: 10.1093.
    PubMed    


  674. OPITZ CA, Turcan S
    From anti-aging drugs to cancer therapy: Is there a potential for sirtuin activators in gliomas?
    Neuro Oncol. 2020 Oct 16. pii: 5924499. doi: 10.1093.
    PubMed    


  675. ALNAHHAS I, Rayi A, Ong S, Giglio P, et al
    Management of gliomas in patients with Lynch Syndrome.
    Neuro Oncol. 2020 Oct 16. pii: 5924485. doi: 10.1093.
    PubMed    


  676. CHAMBERLAIN MC
    Leptomeningeal metastases: how best to assess response.
    Neuro Oncol. 2020;22:1417-1418.
    PubMed    


  677. ROSSI M, Gay L, Ambrogi F, Nibali MC, et al
    Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas.
    Neuro Oncol. 2020 Oct 13. pii: 5922564. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  678. DAS S
    The ethics of neuro-oncology in the era of COVID-19: lessons to be learned.
    Neuro Oncol. 2020;22:1399.
    PubMed    


  679. XU W, Hu X, Zhang J
    Letter regarding article "Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion".
    Neuro Oncol. 2020;22:1400-1401.
    PubMed    


  680. KOTECHA R, Yomo S, Suh JH
    Response to letter regarding "Stereotactic radiosurgery for nonfunctioning pituitary adenomas: meta-analysis and International Society of Stereotactic Radiosurgery (ISRS) practice opinion".
    Neuro Oncol. 2020;22:1402-1403.
    PubMed    


  681. TSANG DS, Kim L, Liu ZA, Janzen L, et al
    Intellectual changes after radiation for children with brain tumors: which brain structures are most important?
    Neuro Oncol. 2020 Sep 16. pii: 5906521. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  682. GUERREIRO STUCKLIN AS, Mueller S
    Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
    Neuro Oncol. 2020 Aug 25. pii: 5896906. doi: 10.1093.
    PubMed    


  683. BOHM AK, DePetro J, Binding CE, Gerber A, et al
    In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
    Neuro Oncol. 2020;22:1150-1161.
    PubMed     Abstract available


  684. SHI C, Ye Z, Han J, Ye X, et al
    BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
    Neuro Oncol. 2020;22:1114-1125.
    PubMed     Abstract available


  685. WICK A, Kessler T, Platten M, Meisner C, et al
    Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Neuro Oncol. 2020;22:1162-1172.
    PubMed     Abstract available


    July 2020
  686. KARREMAN MA, Winkler F
    Targeting an adhesion molecule to prevent brain colonization of lung cancer.
    Neuro Oncol. 2020;22:899-900.
    PubMed    


  687. GEURTS M, van den Bent MJ
    Fast-growing oligodendrogliomas are aggressive tumors-the real life biomarker?
    Neuro Oncol. 2020;22:907-908.
    PubMed    


  688. COLO F, Larrouquere L, Rivoirard R, Loiseau H, et al
    Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults.
    Neuro Oncol. 2020;22:1046-1047.
    PubMed    


  689. JAIN R, Johnson DR, Patel SH, Castillo M, et al
    "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Neuro Oncol. 2020;22:936-943.
    PubMed     Abstract available


  690. ROUX A, Tauziede-Espariat A, Zanello M, Peeters S, et al
    Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Neuro Oncol. 2020;22:993-1005.
    PubMed     Abstract available


    June 2020
  691. BENNETT J, Bouffet E
    Neuro-oncology in adolescents and young adults-an unmet need.
    Neuro Oncol. 2020;22:752-753.
    PubMed    


  692. HU LS, Swanson KR
    Roadmap for the clinical integration of radiomics in neuro-oncology.
    Neuro Oncol. 2020;22:743-745.
    PubMed    


    March 2020
  693. KOTECHA R, Sahgal A, Rubens M, De Salles A, et al
    Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.
    Neuro Oncol. 2020;22:318-332.
    PubMed     Abstract available


  694. LASOCKI A, Khoo C, Lau PKH, Kok DL, et al
    High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges.
    Neuro Oncol. 2020;22:423-432.
    PubMed     Abstract available


    February 2020
  695. OSTROM QT, Kruchko C, Barnholtz-Sloan JS
    Pilocytic astrocytomas: where do they belong in cancer reporting?
    Neuro Oncol. 2020;22:298-300.
    PubMed    


    January 2020
  696. TEW BY, Legendre C, Schroeder MA, Triche T, et al
    Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.
    Neuro Oncol. 2020;22:70-83.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: